diff --git a/src/main/java/com/stm/salesfast/backend/SecurityConfig.java b/src/main/java/com/stm/salesfast/backend/SecurityConfig.java
index 7e8146b..c314ea4 100644
--- a/src/main/java/com/stm/salesfast/backend/SecurityConfig.java
+++ b/src/main/java/com/stm/salesfast/backend/SecurityConfig.java
@@ -77,7 +77,8 @@ class SecurityConfig extends WebSecurityConfigurerAdapter {
 				new AntPathRequestMatcher("/allpitches"),
 				new AntPathRequestMatcher("/getpitchforappointment"),
 				new AntPathRequestMatcher("/updatemeetingpitch"),
-				new AntPathRequestMatcher("/filterparameters")
+				new AntPathRequestMatcher("/filterparameters"),
+				new AntPathRequestMatcher("/getpastappointments")
 				};
 
 		@Override
diff --git a/src/main/java/com/stm/salesfast/backend/controllers/AppointmentController.java b/src/main/java/com/stm/salesfast/backend/controllers/AppointmentController.java
index a764e3f..4115664 100644
--- a/src/main/java/com/stm/salesfast/backend/controllers/AppointmentController.java
+++ b/src/main/java/com/stm/salesfast/backend/controllers/AppointmentController.java
@@ -28,6 +28,7 @@ import com.stm.salesfast.backend.entity.AppointmentEntity;
 import com.stm.salesfast.backend.entity.FollowupAppointmentUpdateEntity;
 import com.stm.salesfast.backend.entity.FutureAppointmentUpdateEntity;
 import com.stm.salesfast.backend.entity.MeetingExperienceEntity;
+import com.stm.salesfast.backend.entity.PastAppointmentEntity;
 import com.stm.salesfast.backend.entity.PitchViewEntity;
 import com.stm.salesfast.backend.services.specs.AlignmentFetchService;
 import com.stm.salesfast.backend.services.specs.AppointmentService;
@@ -90,6 +91,13 @@ public class AppointmentController {
 		return "showappointment";
 	}
 	
+	@RequestMapping(value="/showfutureappointments", method=RequestMethod.GET)
+	public String showFutureAppointments(Model model) throws ParseException{
+		List<AppointmentEntity> futureAppointmentsList = appointmentFetchService.getFutureAppointmentToShow(SessionConstants.USER_ID);
+		
+		model.addAttribute("listOfFutureAppointments", futureAppointmentsList);
+		return "showfutureappointment";
+	}
 	
 	@RequestMapping(value="/addmeetingupdate", method=RequestMethod.POST, consumes = "application/json")
 	@ResponseBody
@@ -180,6 +188,13 @@ public class AppointmentController {
 		return "pastappointment";
 	}
 	
+	@RequestMapping(value="/getpastappointments", method=RequestMethod.GET)
+	@ResponseBody
+	public PastAppointmentEntity[] getPastAppointments() throws ParseException{
+		List<PastAppointmentEntity> pastAppointments = appointmentFetchService.getPastAppointmentToShow(SessionConstants.USER_ID);
+		for(PastAppointmentEntity eachPastApp : pastAppointments) log.info("Past Appointments : "+eachPastApp);
+		return pastAppointments.toArray(new PastAppointmentEntity[pastAppointments.size()]);
+	}
 }
 
 
diff --git a/src/main/java/com/stm/salesfast/backend/dao/impl/AppointmentDaoImpl.java b/src/main/java/com/stm/salesfast/backend/dao/impl/AppointmentDaoImpl.java
index 7827252..a8f9ccc 100644
--- a/src/main/java/com/stm/salesfast/backend/dao/impl/AppointmentDaoImpl.java
+++ b/src/main/java/com/stm/salesfast/backend/dao/impl/AppointmentDaoImpl.java
@@ -73,6 +73,10 @@ public class AppointmentDaoImpl implements AppointmentDao {
 			+ "WHERE physicianId = ? AND hasPitch = 1";
 	private static final String FETCH_ALL_HAVING_PITCH = "SELECT * FROM appointment "
 			+ "WHERE hasPitch = 1";
+	private static final String FETCH_PAST_APPOINTMENTS = "SELECT * FROM appointment "
+			+ "WHERE userId = ? AND "
+			+ "date < DATE_SUB(NOW(),INTERVAL 0 YEAR) "
+			+ "ORDER BY date desc";
 	
 	
 	@Override
@@ -180,6 +184,23 @@ public class AppointmentDaoImpl implements AppointmentDao {
 		}
 		return null;
 	}
+	
+	/**
+	 * This method returns appointments of a user based on whether
+	 * he/she has entered meeting update or meeting experience details 
+	 * */
+	@Override
+	public List<AppointmentDto> getPastAppointmentByUserId(int userId) {
+		// TODO Auto-generated method stub
+		try{
+			return jdbcTemplate.query(FETCH_PAST_APPOINTMENTS, (rs, rownnum)->{
+				return new AppointmentDto(rs.getInt("appointmentId"), rs.getTime("startTime"), rs.getTime("endTime"), rs.getDate("date"), rs.getInt("physicianId"), userId, rs.getInt("productId"), rs.getString("confirmationStatus"), rs.getString("zip"),rs.getString("cancellationReason"), rs.getString("additionalNotes"), rs.getBoolean("hasMeetingUpdate"),rs.getBoolean("hasMeetingExperienceFromSR"),rs.getBoolean("hasMeetingExperienceFromPH"), rs.getBoolean("hasPitch"));
+			}, userId);
+		}catch(DataAccessException e){
+			e.printStackTrace();
+		}
+		return null;
+	}
 
 	@Override
 	public AppointmentDto getAppointmentByPhysicianId(int physicianId) {
diff --git a/src/main/java/com/stm/salesfast/backend/dao/impl/MeetingUpdateDaoImpl.java b/src/main/java/com/stm/salesfast/backend/dao/impl/MeetingUpdateDaoImpl.java
index b37061b..14d8c4e 100644
--- a/src/main/java/com/stm/salesfast/backend/dao/impl/MeetingUpdateDaoImpl.java
+++ b/src/main/java/com/stm/salesfast/backend/dao/impl/MeetingUpdateDaoImpl.java
@@ -34,6 +34,10 @@ public class MeetingUpdateDaoImpl implements MeetingUpdateDao {
 													+ "(physicianId, productId) IN "
 													+ "(SELECT physicianId, productId from appointment "
 													+ " WHERE userId = ?)";
+	private static final String FETCH_STATUS_FOR_APPOINTMENTS = "SELECT status from meeting_update  "
+													+ "WHERE appointmentId in "
+													+ "(SELECT appointmentId from appointment "
+													+ "WHERE userId = ? AND physicianId = ?)";
 	
 	@Autowired
 	JdbcTemplate jdbcTemplate;
@@ -128,5 +132,19 @@ public class MeetingUpdateDaoImpl implements MeetingUpdateDao {
 		return null;
 	}
 	
+	@Override
+	public List<String> getStatusesByAppointments(int userId, int physicianId) {
+		// TODO Auto-generated method stub
+		try{
+			return jdbcTemplate.query(FETCH_STATUS_FOR_APPOINTMENTS, (rs, rownum) -> {
+					return rs.getString("status");
+				}, userId);
+			
+		}catch(DataAccessException e){
+			e.printStackTrace();
+		}
+		return null;
+	}
+	
 	
 }
diff --git a/src/main/java/com/stm/salesfast/backend/dao/specs/AppointmentDao.java b/src/main/java/com/stm/salesfast/backend/dao/specs/AppointmentDao.java
index c97273c..aac175d 100644
--- a/src/main/java/com/stm/salesfast/backend/dao/specs/AppointmentDao.java
+++ b/src/main/java/com/stm/salesfast/backend/dao/specs/AppointmentDao.java
@@ -47,6 +47,8 @@ public interface AppointmentDao {
 
 	public List<AppointmentDto> getAppointmentByPhysician(int physicianId);
 
-	List<AppointmentDto> getAllAppointmentHavingPitch();
+	public List<AppointmentDto> getAllAppointmentHavingPitch();
+
+	public List<AppointmentDto> getPastAppointmentByUserId(int userId);
 	
 }
diff --git a/src/main/java/com/stm/salesfast/backend/entity/PastAppointmentEntity.java b/src/main/java/com/stm/salesfast/backend/entity/PastAppointmentEntity.java
new file mode 100644
index 0000000..6c842de
--- /dev/null
+++ b/src/main/java/com/stm/salesfast/backend/entity/PastAppointmentEntity.java
@@ -0,0 +1,25 @@
+package com.stm.salesfast.backend.entity;
+
+import java.sql.Date;
+import java.util.List;
+
+import lombok.AllArgsConstructor;
+import lombok.Data;
+import lombok.NoArgsConstructor;
+import lombok.ToString;
+
+@AllArgsConstructor
+@NoArgsConstructor
+@Data
+@ToString
+public class PastAppointmentEntity {
+	private int physicianId;
+	private String physicianName;
+	private int productId;
+	private String productName;
+	private Date date;
+	private String meetingStatus;
+	private List<String> reasonsBySalesRep;
+	private List<String> reasonsByPhysician;
+	private PitchViewEntity pitch;
+}
diff --git a/src/main/java/com/stm/salesfast/backend/services/impl/AlignmentFetchServiceImpl.java b/src/main/java/com/stm/salesfast/backend/services/impl/AlignmentFetchServiceImpl.java
index 5de5369..80b7ee4 100644
--- a/src/main/java/com/stm/salesfast/backend/services/impl/AlignmentFetchServiceImpl.java
+++ b/src/main/java/com/stm/salesfast/backend/services/impl/AlignmentFetchServiceImpl.java
@@ -75,6 +75,7 @@ public class AlignmentFetchServiceImpl implements AlignmentFetchService {
 		List<AlignmentsDto> alignmentsByUserId = alignmentDao.getAlignmentByUserIdNotInAppointments(userId);
 		List<AlignedPhysicianEntity> alignedPhysicians = new ArrayList<AlignedPhysicianEntity>();
 		for(AlignmentsDto eachAlignment : alignmentsByUserId){
+			
 			PhysicianStgDto physicianDto = physicianDao.getBy(eachAlignment.getPhysicianId());
 			alignedPhysicians.add(new AlignedPhysicianEntity(physicianDto,
 					productService.getProductById(eachAlignment.getProductId()).getProductName(),
diff --git a/src/main/java/com/stm/salesfast/backend/services/impl/AppointmentServiceImpl.java b/src/main/java/com/stm/salesfast/backend/services/impl/AppointmentServiceImpl.java
index f2f0454..e474fff 100644
--- a/src/main/java/com/stm/salesfast/backend/services/impl/AppointmentServiceImpl.java
+++ b/src/main/java/com/stm/salesfast/backend/services/impl/AppointmentServiceImpl.java
@@ -17,15 +17,21 @@ import com.stm.salesfast.backend.controllers.LoginController;
 import com.stm.salesfast.backend.dao.specs.AlignmentsDao;
 import com.stm.salesfast.backend.dao.specs.AppointmentDao;
 import com.stm.salesfast.backend.dto.AppointmentDto;
+import com.stm.salesfast.backend.dto.MeetingUpdateDto;
 import com.stm.salesfast.backend.dto.PhysicianStgDto;
 import com.stm.salesfast.backend.dto.ProductDto;
 import com.stm.salesfast.backend.dto.UserDto;
 import com.stm.salesfast.backend.entity.AlignedPhysicianFollowUpEntity;
 import com.stm.salesfast.backend.entity.AppointmentEntity;
+import com.stm.salesfast.backend.entity.PastAppointmentEntity;
+import com.stm.salesfast.backend.entity.PitchViewEntity;
 import com.stm.salesfast.backend.services.specs.AlignmentFetchService;
 import com.stm.salesfast.backend.services.specs.AppointmentService;
+import com.stm.salesfast.backend.services.specs.MeetingExperienceService;
+import com.stm.salesfast.backend.services.specs.MeetingUpdateService;
 import com.stm.salesfast.backend.services.specs.NotificationService;
 import com.stm.salesfast.backend.services.specs.PhysicianFetchService;
+import com.stm.salesfast.backend.services.specs.PitchesService;
 import com.stm.salesfast.backend.services.specs.ProductFetchService;
 import com.stm.salesfast.backend.services.specs.UserAccountService;
 import com.stm.salesfast.backend.services.specs.UserDetailService;
@@ -63,6 +69,15 @@ public class AppointmentServiceImpl implements AppointmentService {
 	@Autowired
 	NotificationService notificationService;
 	
+	@Autowired
+	MeetingUpdateService meetingUpdate;
+
+	@Autowired
+	MeetingExperienceService meetingExp;
+
+	@Autowired
+	PitchesService pitch;
+	
 	@Override
 	public void addAppointment(int physId, Time startTime, Time endTime, Date date,  String confirmationStatus, int productId, String additionalNotes) throws ParseException {
 		// TODO Auto-generated method stub
@@ -100,7 +115,7 @@ public class AppointmentServiceImpl implements AppointmentService {
 		for(AppointmentDto eachAppointment : appointmentDtos){
 			PhysicianStgDto physicianDto = physicianService.getPhysicianById(eachAppointment.getPhysicianId());
 			ProductDto productDto = productFetchService.getProductById(eachAppointment.getProductId());
-			if(eachAppointment.getDate().getTime() <= SalesFastUtilities.getCurrentDate().getTime()){
+			if(eachAppointment.getDate().getTime() == SalesFastUtilities.getCurrentDate().getTime()){
 				todaysAppointmentEntitiesList.add(new AppointmentEntity(eachAppointment.getAppointmnetId(),
 						physicianDto.getPhysicianId(),
 						physicianDto.getFirstName()+" "+physicianDto.getLastName(), 
@@ -157,6 +172,35 @@ public class AppointmentServiceImpl implements AppointmentService {
 		}
 		return futureAppointmentEntitiesList;
 	}
+
+	/**
+	 * This method returns PAST DATE's appointments of a user based  
+	 * @throws ParseException 
+	 * */
+	@Override
+	public List<PastAppointmentEntity> getPastAppointmentToShow(int userId) throws ParseException {
+		// TODO Auto-generated method stub
+		List<AppointmentDto> appointmentDtos = appointmentDao.getPastAppointmentByUserId(userId);
+		List<PastAppointmentEntity> pastAppointmentEntitiesList = new ArrayList<>();
+		for(AppointmentDto eachAppointment : appointmentDtos){
+			PhysicianStgDto physicianDto = physicianService.getPhysicianById(eachAppointment.getPhysicianId());
+			ProductDto productDto = productFetchService.getProductById(eachAppointment.getProductId());
+			MeetingUpdateDto meetingUpdateDto = meetingUpdate.getMeetingUpdateByAppointmentId(eachAppointment.getAppointmnetId());
+			String meetingStatus = (meetingUpdateDto == null) ? "STATUS NA" : meetingUpdateDto.getStatus();
+			pastAppointmentEntitiesList.add(new PastAppointmentEntity(
+						physicianDto.getPhysicianId(),
+						physicianDto.getFirstName()+" "+physicianDto.getLastName(),
+						productDto.getProductId(),
+						productDto.getProductName(),
+						eachAppointment.getDate(),
+						meetingStatus,
+						meetingExp.salesRepResponse(eachAppointment.getAppointmnetId()),
+						meetingExp.physicianResponse(eachAppointment.getAppointmnetId()),
+						pitch.getPitchForAppointment(eachAppointment.getAppointmnetId())
+					));
+		}
+		return pastAppointmentEntitiesList;
+	}
 	
 	/**
 	 * This method returns ALL appointments of a user based on whether
diff --git a/src/main/java/com/stm/salesfast/backend/services/impl/MeetingExperienceServiceImpl.java b/src/main/java/com/stm/salesfast/backend/services/impl/MeetingExperienceServiceImpl.java
index 19bd793..5f59ada 100644
--- a/src/main/java/com/stm/salesfast/backend/services/impl/MeetingExperienceServiceImpl.java
+++ b/src/main/java/com/stm/salesfast/backend/services/impl/MeetingExperienceServiceImpl.java
@@ -1,5 +1,6 @@
 package com.stm.salesfast.backend.services.impl;
 
+import java.util.ArrayList;
 import java.util.List;
 
 import org.slf4j.Logger;
@@ -79,6 +80,54 @@ public class MeetingExperienceServiceImpl implements MeetingExperienceService {
 	}
 	
 	@Override
+	public List<String> salesRepResponse(int appointmentId){
+		List<String> salesRepResponse = new ArrayList<>();
+		List<MeetingExperienceDto> meetingExp =  fetchMeetingExperienceByAppointmentId(appointmentId);
+		for(MeetingExperienceDto eachMeetingExp : meetingExp){
+			if(eachMeetingExp.isSalesRepEntry()){
+				if(eachMeetingExp.isLikedTheProduct()) salesRepResponse.add("Physician liked the product.");
+				else salesRepResponse.add("Physician did not liked the product.");
+				if(eachMeetingExp.isLikedPriceAffordability()) salesRepResponse.add("Physician liked the fact that medicine was affordable.");
+				else salesRepResponse.add("Physician did not find medicine affordable.");
+				if(eachMeetingExp.isLikedPresentation()) salesRepResponse.add("Physician liked the presentation.");
+				else salesRepResponse.add("Physician did not like the presentation.");
+				if(eachMeetingExp.isImpressiveCompanyReputation()) salesRepResponse.add("Physician was impressed by company's reputation.");
+				else salesRepResponse.add("Physician was not impressed by company's reputation.");
+				if(eachMeetingExp.isImpressiveLessSideEffects()) salesRepResponse.add("Physician liked that medicine has less side effects.");
+				else salesRepResponse.add("Physician was not impressed beacuse he thinks medicine has many side effects.");
+				if(eachMeetingExp.isSalesRepConfidence()) salesRepResponse.add("Physician liked your confidence during presentation.");
+				else salesRepResponse.add("You need to be more confident while pitching.");
+			}
+		}
+		
+		return salesRepResponse;
+	}
+	
+	@Override
+	public List<String> physicianResponse(int appointmentId){
+		List<String> physicianResponse = new ArrayList<>();
+		List<MeetingExperienceDto> meetingExp =  fetchMeetingExperienceByAppointmentId(appointmentId);
+		for(MeetingExperienceDto eachMeetingExp : meetingExp){
+			if(eachMeetingExp.isPhysicianEntry()){
+				if(eachMeetingExp.isLikedTheProduct()) physicianResponse.add("Physician liked the product.");
+				else physicianResponse.add("Physician did not liked the product.");
+				if(eachMeetingExp.isLikedPriceAffordability()) physicianResponse.add("Physician liked the fact that medicine was affordable.");
+				else physicianResponse.add("Physician did not find medicine affordable.");
+				if(eachMeetingExp.isLikedPresentation()) physicianResponse.add("Physician liked the presentation.");
+				else physicianResponse.add("Physician did not like the presentation.");
+				if(eachMeetingExp.isImpressiveCompanyReputation()) physicianResponse.add("Physician was impressed by company's reputation.");
+				else physicianResponse.add("Physician was not impressed by company's reputation.");
+				if(eachMeetingExp.isImpressiveLessSideEffects()) physicianResponse.add("Physician liked that medicine has less side effects.");
+				else physicianResponse.add("Physician was not impressed beacuse he thinks medicine has many side effects.");
+				if(eachMeetingExp.isSalesRepConfidence()) physicianResponse.add("Physician liked your confidence during presentation.");
+				else physicianResponse.add("You need to be more confident while pitching.");
+			}
+		}
+		
+		return physicianResponse;
+	}
+	
+	@Override
 	public int countOfRecords(boolean forPhysicianEntries, boolean forSalesRepEntries){
 		if(forPhysicianEntries && forSalesRepEntries) return meetingExperienceDao.countAll();
 		else if(forPhysicianEntries) return meetingExperienceDao.countAllPhy();
diff --git a/src/main/java/com/stm/salesfast/backend/services/impl/PitchesServiceImpl.java b/src/main/java/com/stm/salesfast/backend/services/impl/PitchesServiceImpl.java
index 6385eb2..01018f7 100644
--- a/src/main/java/com/stm/salesfast/backend/services/impl/PitchesServiceImpl.java
+++ b/src/main/java/com/stm/salesfast/backend/services/impl/PitchesServiceImpl.java
@@ -108,8 +108,11 @@ public class PitchesServiceImpl implements PitchesService{
 	@Override
 	public PitchViewEntity getPitchForAppointment(int appointmentId){
 		PitchesDto pitchDto = pitchDao.getPitchByAppointmentId(appointmentId);
-		String fileLocation = ConstantValues.PITCH_DOCS_PATH+pitchDto.getFileName();
-		return new PitchViewEntity(pitchDto.getPitchesId(), pitchDto.getAppointmentId(), pitchDto.getMeetingStatus(), fileLocation, pitchDto.getPitchScore());
+		if(pitchDto == null) return null;
+		else{
+			String fileLocation = ConstantValues.PITCH_DOCS_PATH+pitchDto.getFileName();
+			return new PitchViewEntity(pitchDto.getPitchesId(), pitchDto.getAppointmentId(), pitchDto.getMeetingStatus(), fileLocation, pitchDto.getPitchScore());
+		}
 	}
 	
 	@Override
diff --git a/src/main/java/com/stm/salesfast/backend/services/specs/AppointmentService.java b/src/main/java/com/stm/salesfast/backend/services/specs/AppointmentService.java
index 4a844b7..ecb5591 100644
--- a/src/main/java/com/stm/salesfast/backend/services/specs/AppointmentService.java
+++ b/src/main/java/com/stm/salesfast/backend/services/specs/AppointmentService.java
@@ -8,6 +8,7 @@ import java.util.List;
 import com.stm.salesfast.backend.dto.AppointmentDto;
 import com.stm.salesfast.backend.entity.AlignedPhysicianFollowUpEntity;
 import com.stm.salesfast.backend.entity.AppointmentEntity;
+import com.stm.salesfast.backend.entity.PastAppointmentEntity;
 
 public interface AppointmentService {
 
@@ -66,5 +67,8 @@ public interface AppointmentService {
 	List<AppointmentDto> getAppointmentsByPhysician(int physicianId);
 
 	List<AppointmentDto> getAllAppointmentsHavingPitch();
+
+	List<PastAppointmentEntity> getPastAppointmentToShow(int userId)
+			throws ParseException;
 	
 }
diff --git a/src/main/java/com/stm/salesfast/backend/services/specs/MeetingExperienceService.java b/src/main/java/com/stm/salesfast/backend/services/specs/MeetingExperienceService.java
index 5ddab10..2a37fd3 100644
--- a/src/main/java/com/stm/salesfast/backend/services/specs/MeetingExperienceService.java
+++ b/src/main/java/com/stm/salesfast/backend/services/specs/MeetingExperienceService.java
@@ -44,4 +44,8 @@ public interface MeetingExperienceService {
 	int getCountForRepsConfidence_Lost();
 
 	int getCountOrgReputation_Lost();
+
+	List<String> physicianResponse(int appointmentId);
+
+	List<String> salesRepResponse(int appointmentId);
 }
diff --git a/src/main/resources/templates/pastappointment.html b/src/main/resources/templates/pastappointment.html
index 7625ccc..3cb4379 100644
--- a/src/main/resources/templates/pastappointment.html
+++ b/src/main/resources/templates/pastappointment.html
@@ -3,7 +3,7 @@
 <head>
 <!-- Header to include css -->
 <div th:replace="fragments/header :: commonhead"></div>
-<link rel="stylesheet" type="text/css" href="resources/app/css/pastappointments.css"/>
+<link rel="stylesheet" type="text/css" href="resources/app/css/pastappointment.css"/>
 <link rel="stylesheet" type="text/css" href="resources/app/css/toggleyesnoswitch.css"/>
 <meta charset="ISO-8859-1" />
 <title>SalesFast Home</title>
@@ -15,23 +15,38 @@
 		<div class="left-nav" id="cssmenu">
 			<ul class="left-menu-ul">
 				<li class='active today-appointment-li' ><a href='/showappointments'><span>TODAY's APPOINTMENTS</span></a></li>
-				<li class='last future-appointment-li'><a href='#'><span>FUTURE APPOINTMENTS</span></a></li>
+				<li class='last future-appointment-li'><a href='/showfutureappointments'><span>FUTURE APPOINTMENTS</span></a></li>
 				<li class='last past-appointment-li'><a href='/pastappointments'><span>PAST APPOINTMENTS</span></a></li>
 			</ul>
 		</div>
 		<div class="container" id="layout">
 			<div class="row row-header page-header"><h3>Your past appointments</h3></div>
-			<div class="future-appointment-div" style="display: none;">
-				<div class="row row-header page-header"><h3>Future Appointments!</h3></div>
-				<div class="row future-appointment-div"><div th:replace="futureappointmentmodal :: futureappointmentmodal-body"></div></div>
+			<div class="row">
+				<div class="col-lg-12 col-sm-12">
+					<table id="past-appointments-table" class="table table-bordered past-appointment-table-class">
+						<thead>
+							<tr>
+								<th style="display:none" class="physician-id">Physician Id</th>
+								<th>Physician Name</th>
+								<th style="display:none" class="product-id">Product Id</th>
+								<th>Product</th>
+								<th>Date</th>
+								<th>Status</th>
+								<th>Further Details</th>				
+							</tr>
+						</thead>
+						<tbody>
+						</tbody>
+					</table>
+				</div>
 			</div>
+					
 		</div>
 	</div>
 	
-							<!-- Modal for viewing future appointments -->
-	<div th:replace="futureappointmentmodal :: futureappointmentmodal"></div>
 	
-
+			<!-- Modal for VIEWING PAST APPOINTMENT DETAILS-->
+	<div th:replace="pastappointmentdetailmodal :: past-appointment-details-modal"></div>
 <!-- Common footer -->
 <div th:replace="fragments/footer :: footer"></div>
 <script  type="text/javascript" src="resources/app/js/pastappointment.js"></script>
diff --git a/src/main/resources/templates/pastappointmentdetailmodal.html b/src/main/resources/templates/pastappointmentdetailmodal.html
new file mode 100644
index 0000000..0124786
--- /dev/null
+++ b/src/main/resources/templates/pastappointmentdetailmodal.html
@@ -0,0 +1,47 @@
+<!DOCTYPE html>
+<html>
+<head>
+</head>
+<body>
+	<div class="modal fade" id="pastappointment-details-modal" role="dialog" data-edit-mode="false" th:fragment="past-appointment-details-modal">
+		<div class="modal-dialog" role="document">
+			<div class="modal-content">
+				<div class="modal-header">
+					<button type="button" class="close" data-dismiss="modal"
+						aria-label="Close">
+						<span aria-hidden="true">&times;</span>
+					</button>
+					<h4 class="modal-title" id="furtherdetailmodal">Further Details</h4>
+				</div>
+				<div class="modal-custom-header-1 modal-header further-detail-modal-header">
+					<h5 class="modal-title">Your experience about meeting</h5>
+				</div>
+				<div class="modal-body modal-body-1 meeting-exp-modal-body">
+					<ul class="salesrep-response">
+						
+					</ul>
+				</div>
+				<div class="modal-custom-header-2 modal-header further-detail-modal-header">
+					<h5 class="modal-title">Physician's experience about meeting</h5>
+				</div>
+				<div class="modal-body modal-body-2  meeting-exp-modal-body">
+					<ul class="physician-response">
+						
+					</ul>
+				</div>
+				<div class="modal-custom-header-3 modal-header further-detail-modal-header">
+					<h5 class="modal-title">Your pitch for the meeting</h5>
+				</div>
+				<div class="modal-body modal-body-3">
+					
+				</div>
+				
+				
+				<div class="modal-footer">
+					<button id="further-detail-cancel-button" type="button" class="btn btn-default" data-dismiss="modal">Cancel</button>
+				</div>
+			</div>
+		</div>
+	</div>
+</body>
+</html>
\ No newline at end of file
diff --git a/src/main/resources/templates/products.html b/src/main/resources/templates/products.html
index 42b73f8..81fb0bc 100644
--- a/src/main/resources/templates/products.html
+++ b/src/main/resources/templates/products.html
@@ -24,7 +24,7 @@
 			<div class="row product-selector-div">
 				<div class="product-selection-div">
 					<div class="product-selector-label">SELECT A PRODUCT.</div>
-					<select class="product-selector validate-ele" name="product">
+					<select class="product-selector validate-ele" id="product-selector-id" name="product">
 						<option disabled="disabled" selected="selected" value="none"> -- select a product-- </option>
 					</select>
 				</div>
diff --git a/src/main/resources/templates/showalignments.html b/src/main/resources/templates/showalignments.html
index 7b18d40..d4a8ab0 100644
--- a/src/main/resources/templates/showalignments.html
+++ b/src/main/resources/templates/showalignments.html
@@ -18,38 +18,59 @@
 				<table id="aligned-physician-table" class="table table-striped table-bordered">
 					<thead>
 						<tr>
-							<th style="display:none">Physician Id</th>
+							<th style="display:none">Importance Factor</th>
+							<th class="physician-id" style="display:none">Physician Id</th>
 							<th>Physician Name</th>
-							<th>Email Id</th>
-							<th>Contact</th>
-							<th>Address</th>
+							<th>Contact Details</th>
+							<th style="display:none">Email Id</th>
+							<th style="display:none">Contact</th>
+							<th style="display:none">Address</th>
 							<th style="display:none">City</th>
 							<th style="display:none">State</th>
 							<th style="display:none">ZIP</th>
 							<th style="display:none">Medical Field</th>
 							<th>Product</th>
-							<th style="display:none">Product Id</th>
+							<th class="product-id" style="display:none">Product Id</th>
 							<th>Is a new Physician?</th>
 							<th>Date</th>
 							<th>Time</th>
 							<th>Appointment Status</th>
 							<th>Notes</th>
-							<th style="display:none">Importance Factor</th>
+							<th>Past Meetings</th>
 						</tr>
 					</thead>
 					<tbody>
 						<tr th:each="eachAlignment : ${listOfAlignedPhysician}">
-							<td style="display:none" th:text="${eachAlignment.physicianId}"></td>
+							<td class="importance-factor" style="display:none" th:text="${eachAlignment.importanceFactor}"></td>
+							<td class="physician-id" style="display:none" th:text="${eachAlignment.physicianId}"></td>
 							<td class="physician-name" th:text="${eachAlignment.firstName} + ' '+${eachAlignment.lastName}"></td>
-							<td th:text="${eachAlignment.email}"></td>
-							<td th:text="${eachAlignment.contactNumber}"></td>
-							<td th:text="${eachAlignment.addressLineOne} +' '+ ${eachAlignment.addressLineTwo}+' '+${eachAlignment.city}+' '+${eachAlignment.zip}"></td>
+							<td class="contact-details">
+								<div class="aligned-phys-contact-td">
+									<div class="phys-contact-detail-btn">
+										<button type="button" class="btn btn-default btn-md show-contact form-control">
+											<span class="glyphicon glyphicon-plus" aria-hidden="true"></span>
+											<span class="button-value">Show Contact Details</span>
+										</button>
+									</div>
+									<div class="aligned-physician-contact"  style="display: none">
+										<div class="phys-address"><span class="contactdetail-label">Address : </span><span class="contactdetail-content" 
+										th:text="${eachAlignment.addressLineOne} +' '+ ${eachAlignment.addressLineTwo}+' '+${eachAlignment.city}+' '+${eachAlignment.zip}"></span></div>
+										<div class="phys-phone"><span class="contactdetail-label">Phone : </span><span class="contactdetail-content" 
+										th:text="${eachAlignment.contactNumber}"></span></div>
+										<div class="phys-email"><span class="contactdetail-label">Email : </span><span class="contactdetail-content" 
+										th:text="${eachAlignment.email}"></span></div>
+									</div>
+								</div>
+							</td>
+							<td style="display:none" th:text="${eachAlignment.email}"></td>
+							<td style="display:none" th:text="${eachAlignment.contactNumber}"></td>
+							<td style="display:none" th:text="${eachAlignment.addressLineOne} +' '+ ${eachAlignment.addressLineTwo}+' '+${eachAlignment.city}+' '+${eachAlignment.zip}"></td>
 							<td style="display:none" th:text="${eachAlignment.city}"></td>
 							<td style="display:none" th:text="${eachAlignment.state}"></td>
 							<td style="display:none" th:text="${eachAlignment.zip}"></td>
 							<td style="display:none" th:text="${eachAlignment.medicalField}"></td>
 							<td th:text="${eachAlignment.productName}"></td>
-							<td style="display:none" th:text="${eachAlignment.productId}"></td>
+							<td class="product-id" style="display:none" th:text="${eachAlignment.productId}"></td>
 							<td th:unless="${eachAlignment.isNew}" th:text="NO"></td>
 							<td th:if="${eachAlignment.isNew}" th:text="YES"></td>
 							<td><input class="appointment-date appointment-paramaters" type="date" disabled="disabled"/></td>
@@ -69,8 +90,14 @@
 								</div>
 							</td>
 							<td><textarea name="id" class="form-control appointment-notes-class appointment-paramaters" 
-							id="appointment-notes-id" placeholder="Additional notes" rows="2" required="required" disabled="disabled"></textarea></td>
-							<td class="importance-factor" style="display:none" th:text="${eachAlignment.importanceFactor}"></td>
+								id="appointment-notes-id" placeholder="Additional notes" rows="2" required="required" disabled="disabled"></textarea>
+							</td>
+							<td class="past-appointment-redirect-td">
+								<button type="button" class="btn btn-default btn-md redirect-past-appointments form-control">
+									<span class="glyphicon" aria-hidden="true"></span>
+									<span class="button-value">Your past interactions</span>
+								</button>
+							</td>
 						</tr>
 					</tbody>
 				</table>
diff --git a/src/main/resources/templates/showappointment.html b/src/main/resources/templates/showappointment.html
index 5ab49bc..d4894ea 100644
--- a/src/main/resources/templates/showappointment.html
+++ b/src/main/resources/templates/showappointment.html
@@ -15,12 +15,12 @@
 		<div class="left-nav" id="cssmenu">
 			<ul class="left-menu-ul">
 				<li class='active today-appointment-li'><a href='/showappointments'><span>TODAY's APPOINTMENTS</span></a></li>
-				<li class='future-appointment-li'><a href='#'><span>FUTURE APPOINTMENTS</span></a></li>
+				<li class='future-appointment-li'><a href='/showfutureappointments'><span>FUTURE APPOINTMENTS</span></a></li>
 				<li class='last past-appointment-li'><a href='/pastappointments'><span>PAST APPOINTMENTS</span></a></li>
 			</ul>
 		</div>
 		<div class="container" id="layout">
-			<div class="today-appointment-div" style="display: none;">
+			<div class="today-appointment-div">
 				<div class="row row-header page-header"><h3>Your Appointments For Today</h3></div>
 				<div class="row update-buttons-row">
 					<div class="col-lg-12 col-sm-12 table-buttons">
@@ -47,14 +47,14 @@
 							<thead>
 								<tr>
 									<th class="appointment-id" style="display:none">Appointment Id</th>
-									<th style="display:none">Physician Id</th>
+									<th class="physician-id" style="display:none">Physician Id</th>
 									<th>Physician Name</th>
 									<th>Address</th>
 									<th>Contact</th>
 									<th>Email Id</th>
 									<th class="confirmation-status-head">Confirmation Status</th>
 									<th>Time of appointment</th>
-									<th>Product</th>
+									<th class="product-name">Product</th>
 									<th class="meeting-update-flag" style="display:none">Has Meeting Update</th>
 									<th class="meeting-exp-flag" style="display:none">Has Meeting Experience</th>
 									<th>Notes</th>
@@ -65,7 +65,7 @@
 							<tbody>
 								<tr th:each="eachAppointment : ${listOfTodaysAppointments}">
 									<td class="appointment-id" style="display:none" th:text="${eachAppointment.appointmentId}"></td>
-									<td style="display:none" th:text="${eachAppointment.physicianId}"></td>
+									<td class="physician-id" style="display:none" th:text="${eachAppointment.physicianId}"></td>
 									<td class="physician-name-td" th:text="${eachAppointment.physicianName}"></td>
 									<td th:text="${eachAppointment.address}"></td>
 									<td th:text="${eachAppointment.contact}"></td>
@@ -77,7 +77,7 @@
 										<span class="time-label">Ends &nbsp;@ </span>
 										<span  th:text="${eachAppointment.endTime}" class="appointment-end-time-span"></span>
 									</td>
-									<td th:text="${eachAppointment.product}"></td>
+									<td class="product-name-td" th:text="${eachAppointment.product}"></td>
 									<td class="meeting-update-flag" style="display:none" th:text="${eachAppointment.hasMeetingUpdate}"></td>
 									<td class="meeting-exp-flag" style="display:none" th:text="${eachAppointment.hasMeetingExperience}"></td>
 									<td th:text="${eachAppointment.additionalUpdate}"></td>
@@ -106,7 +106,7 @@
 							<table id="aligned-vicinity-physician-table" class="table table-striped table-bordered">
 								<thead>
 									<tr>
-										<th style="display:none">Physician Id</th>
+										<th class="physician-id" style="display:none">Physician Id</th>
 										<th>Physician Name</th>
 										<th>Email Id</th>
 										<th>Contact</th>
@@ -116,7 +116,7 @@
 										<th style="display:none">ZIP</th>
 										<th style="display:none">Medical Field</th>
 										<th>Product</th>
-										<th style="display:none">Product Id</th>
+										<th class="product-id" style="display:none">Product Id</th>
 										<th>Is a new Physician?</th>
 										<th>Date</th>
 										<th>Time</th>
@@ -127,7 +127,7 @@
 								</thead>
 								<tbody>
 									<tr th:each="eachVicinityAlignment : ${listOfPhysInVicinity}">
-										<td style="display:none" th:text="${eachVicinityAlignment.physicianId}"></td>
+										<td class="product-id" style="display:none" th:text="${eachVicinityAlignment.physicianId}"></td>
 										<td th:text="${eachVicinityAlignment.firstName} + ' '+${eachVicinityAlignment.lastName}"></td>
 										<td th:text="${eachVicinityAlignment.email}"></td>
 										<td th:text="${eachVicinityAlignment.contactNumber}"></td>
@@ -137,7 +137,7 @@
 										<td style="display:none" th:text="${eachVicinityAlignment.zip}"></td>
 										<td style="display:none" th:text="${eachVicinityAlignment.medicalField}"></td>
 										<td th:text="${eachVicinityAlignment.productName}"></td>
-										<td style="display:none" th:text="${eachVicinityAlignment.productId}"></td>								
+										<td class="product-id" style="display:none" th:text="${eachVicinityAlignment.productId}"></td>								
 										<td th:unless="${eachVicinityAlignment.isNew}" th:text="NO"></td>
 										<td th:if="${eachVicinityAlignment.isNew}" th:text="YES"></td>
 										<td><input class="appointment-date appointment-paramaters" type="date" disabled="disabled"/></td>
@@ -174,7 +174,7 @@
 						<table id="followup-appointments-table" class="table table-striped table-bordered">
 							<thead>
 								<tr>
-									<th style="display:none">Physician Id</th>
+									<th class="physician-id" style="display:none">Physician Id</th>
 									<th>Physician Name</th>
 									<th>Email Id</th>
 									<th>Contact</th>
@@ -184,7 +184,7 @@
 									<th style="display:none">ZIP</th>
 									<th style="display:none">Medical Field</th>
 									<th>Product</th>
-									<th style="display:none">Product Id</th>
+									<th class="product-id" style="display:none">Product Id</th>
 									<th>Is a new Physician?</th>
 									<th>Date</th>
 									<th>Time</th>
@@ -196,7 +196,7 @@
 							</thead>
 							<tbody>
 								<tr th:each="eachFollowUpAppointment : ${followUpAppointments}">
-									<td style="display:none" th:text="${eachFollowUpAppointment.physicianId}"></td>
+									<td class="physician-id" style="display:none" th:text="${eachFollowUpAppointment.physicianId}"></td>
 									<td th:text="${eachFollowUpAppointment.firstName} + ' '+${eachFollowUpAppointment.lastName}"></td>
 									<td th:text="${eachFollowUpAppointment.email}"></td>
 									<td th:text="${eachFollowUpAppointment.contactNumber}"></td>
@@ -206,7 +206,7 @@
 									<td style="display:none" th:text="${eachFollowUpAppointment.zip}"></td>
 									<td style="display:none" th:text="${eachFollowUpAppointment.medicalField}"></td>
 									<td th:text="${eachFollowUpAppointment.productName}"></td>
-									<td style="display:none" th:text="${eachFollowUpAppointment.productId}"></td>								
+									<td class="product-id" style="display:none" th:text="${eachFollowUpAppointment.productId}"></td>								
 									<td th:unless="${eachFollowUpAppointment.isNew}" th:text="NO"></td>
 									<td th:if="${eachFollowUpAppointment.isNew}" th:text="YES"></td>
 									<td><input class="appointment-date followup-appointment-paramaters" type="date" disabled="disabled" th:value="${eachFollowUpAppointment.followUpDate}"/></td>
@@ -247,8 +247,8 @@
 							<!-- Modal for adding meeting updates -->
 	<div th:replace="addmeetingupdatemodal :: addmeetingupdatemodal"></div>
 	
-							<!-- Modal for viewing future appointments -->
-	<div th:replace="futureappointmentmodal :: futureappointmentmodal"></div>
+							<!-- Modal for viewing future appointments 
+	<div th:replace="futureappointmentmodal :: futureappointmentmodal"></div> -->
 	
 							<!-- Modal for UPLOADING meeting pitch-->
 	<div th:replace="uploadpitchmodal :: upload-meeting-pitch-modal"></div>
@@ -262,6 +262,6 @@
 <!-- Common footer -->
 <div th:replace="fragments/footer :: footer"></div>
 <script  type="text/javascript" src="resources/app/js/showappointments.js"></script>
-<script  type="text/javascript" src="resources/app/js/futureappointment.js"></script>
+<!-- <script  type="text/javascript" src="resources/app/js/futureappointment.js"></script> -->
 </body>
 </html>
\ No newline at end of file
diff --git a/src/main/resources/templates/showfutureappointment.html b/src/main/resources/templates/showfutureappointment.html
new file mode 100644
index 0000000..d00b052
--- /dev/null
+++ b/src/main/resources/templates/showfutureappointment.html
@@ -0,0 +1,47 @@
+<!DOCTYPE html>
+<html xmlns:th="http://www.thymeleaf.org">
+<head>
+<!-- Header to include css -->
+<div th:replace="fragments/header :: commonhead"></div>
+<link rel="stylesheet" type="text/css" href="resources/app/css/appointments.css"/>
+<link rel="stylesheet" type="text/css" href="resources/app/css/toggleyesnoswitch.css"/>
+<meta charset="ISO-8859-1" />
+<title>SalesFast Home</title>
+</head>
+<body>
+	<!-- Common header -->
+	<div th:replace="fragments/header :: header"></div>
+	<div class="outer-container">
+		<div class="left-nav" id="cssmenu">
+			<ul class="left-menu-ul">
+				<li class='active today-appointment-li' ><a href='/showappointments'><span>TODAY's APPOINTMENTS</span></a></li>
+				<li class='last future-appointment-li'><a href='/showfutureappointments'><span>FUTURE APPOINTMENTS</span></a></li>
+				<li class='last past-appointment-li'><a href='/pastappointments'><span>PAST APPOINTMENTS</span></a></li>
+			</ul>
+		</div>
+		<div class="container" id="layout">
+			<div class="future-appointment-div">
+				<div class="row row-header page-header"><h3>Future Appointments!</h3></div>
+				<div class="row future-appointment-div"><div th:replace="futureappointmentmodal :: futureappointmentmodal-body"></div></div>
+			</div>
+		</div>
+	</div>
+	
+							<!-- Modal for viewing future appointments -->
+	<div th:replace="futureappointmentmodal :: futureappointmentmodal"></div>
+	
+						<!-- Modal for UPLOADING meeting pitch-->
+	<div th:replace="uploadpitchmodal :: upload-meeting-pitch-modal"></div>
+	
+							<!-- Modal for VIEWING meeting pitch-->
+	<div th:replace="viewpitchmodal :: view-meeting-pitch-modal"></div>
+	
+							<!-- Modal for entering cancellation reason -->
+	<div th:replace="appointmentcancelmodal :: appointment-cancellation-modal"></div>
+	
+<!-- Common footer -->
+<div th:replace="fragments/footer :: footer"></div>
+<script  type="text/javascript" src="resources/app/js/showappointments.js"></script>
+<script  type="text/javascript" src="resources/app/js/futureappointment.js"></script>
+</body>
+</html>
\ No newline at end of file
diff --git a/src/main/webapp/resources/app/css/alignments.css b/src/main/webapp/resources/app/css/alignments.css
index 8757f25..1cb5522 100644
--- a/src/main/webapp/resources/app/css/alignments.css
+++ b/src/main/webapp/resources/app/css/alignments.css
@@ -33,9 +33,46 @@ td.appointment-time-td{
 }
 
 .appointment-end-time{
-	margin-left: 7px;
+	margin-left: 12px;
 }
 
 span.time-label {
     font-size: smaller;
+}
+select.appointment-status-selector.validate-ele.appointment-paramaters {
+    color: black;
+}
+
+table#aligned-physician-table{
+	font-family: "Trebuchet MS", Arial, Helvetica, sans-serif;
+}
+
+button.btn.btn-default.btn-md.show-contact.form-control {
+    border-radius: 0px;
+        width: 100%;
+    height: 32px;
+    vertical-align: middle;
+}
+
+span.glyphicon.glyphicon-plus {
+    float: left;
+}
+
+.phys-address {
+    display: inline-flex;
+        padding: 0px;
+}
+
+span.contactdetail-label {
+    width: 27%;
+    font-style: italic;
+}
+
+span.contactdetail-content {
+    font-weight: 600;
+    width: 65%;
+}
+
+td.contact-details {
+    width: 19%;
 }
\ No newline at end of file
diff --git a/src/main/webapp/resources/app/css/appointments.css b/src/main/webapp/resources/app/css/appointments.css
index cfab554..274e86c 100644
--- a/src/main/webapp/resources/app/css/appointments.css
+++ b/src/main/webapp/resources/app/css/appointments.css
@@ -1,8 +1,5 @@
 @CHARSET "ISO-8859-1";
 
-
-
-
 .slidedown-alignments{
     margin-left: 14px;
 	text-align: -webkit-auto;
diff --git a/src/main/webapp/resources/app/css/pastappointment.css b/src/main/webapp/resources/app/css/pastappointment.css
index c931ddc..f67cc06 100644
--- a/src/main/webapp/resources/app/css/pastappointment.css
+++ b/src/main/webapp/resources/app/css/pastappointment.css
@@ -5,4 +5,65 @@
 	border-bottom: 2px solid #1910A2;
     padding-top: 1%;
     padding-bottom: 0%;
-} 
\ No newline at end of file
+} 
+
+.past-appointment-table-class>tbody>tr.prescribing-appointment-tr{
+/* 	background-color: #B8EAB5; */
+}
+
+.past-appointment-table-class>tbody>tr.lost-appointment-tr{
+	/* background-color: #F5C9C9; */
+}
+
+table#past-appointments-table, .further-detail-btn-span{
+	font-family: "Trebuchet MS", Arial, Helvetica, sans-serif;
+}
+
+span.further-detail-btn-span {
+    margin-left: 6%;
+}
+
+button.btn.btn-default.btn-md.past-appointment-detail-btn {
+    width: 80%;
+    border-radius: 0px;
+    margin-left: 11%;
+    height: 100%;
+}
+h5.modal-title {
+    font-size: large;
+}
+.modal-header.further-detail-modal-header {
+    border-bottom: 1px solid #000000;
+    padding-bottom: 4px;
+    font-family: serif;
+}
+.modal-body.meeting-exp-modal-body {
+    background: aliceblue;
+}
+.pitch-doc-div {
+    height: 400px;
+}
+object.pdf-doc-object.pdf-doc-object-slidedown {
+    width: 100%;
+    height: 102%;
+}
+
+
+div.modal-body>ul {
+    margin: 0.75em 0;
+    padding: 0 1em;
+    list-style: none;
+    margin-top: -8px;
+}
+div.modal-body>ul>li:before { 
+    content: "";
+    border-color: transparent #111;
+    border-style: solid;
+    border-width: 0.35em 0 0.35em 0.45em;
+    display: block;
+    height: 0;
+    width: 0;
+    left: -1em;
+    top: 0.9em;
+    position: relative;
+}
\ No newline at end of file
diff --git a/src/main/webapp/resources/app/css/products.css b/src/main/webapp/resources/app/css/products.css
index 74aa379..b4e1b2c 100644
--- a/src/main/webapp/resources/app/css/products.css
+++ b/src/main/webapp/resources/app/css/products.css
@@ -140,4 +140,11 @@ button.btn.btn-default.btn-md.show-doc.form-control {
     padding-bottom: 6px;
     margin-bottom: 7px;
     border-bottom-width: thin;
-}
\ No newline at end of file
+}
+button.btn.btn-default.btn-md.show-doc.form-control.product-doc-button-clicked {
+    background: #A4A5CC;
+}
+
+button.btn.btn-default.btn-md.show-doc.form-control {
+    background: white;
+}
diff --git a/src/main/webapp/resources/app/js/futureappointment.js b/src/main/webapp/resources/app/js/futureappointment.js
index 5334ebb..e1b72ca 100644
--- a/src/main/webapp/resources/app/js/futureappointment.js
+++ b/src/main/webapp/resources/app/js/futureappointment.js
@@ -5,8 +5,13 @@ var futureAppointmentTable;
 var averageTravelTime = 30; //minutes
 $(document).ready(function(){
 	
+	$('li.left-menu-selected').removeClass('left-menu-selected');
+	$('li.future-appointment-li').addClass('left-menu-selected');
+	
 	futureAppointmentTable = $('#future-appointment-fixed-physician-table').dataTable();
 	
+	$(".appointment-status-selector").select2();
+	
 	$('#future-appointment-fixed-physician-table').find('tr').each(function(i, val){
 		   if($(val).find('.cancelled-appointment-status').html() == 'CANCELLED'){
 			   $(val).css('background-color','mistyrose');
diff --git a/src/main/webapp/resources/app/js/pastappointment.js b/src/main/webapp/resources/app/js/pastappointment.js
index d5d95ff..d3f427b 100644
--- a/src/main/webapp/resources/app/js/pastappointment.js
+++ b/src/main/webapp/resources/app/js/pastappointment.js
@@ -1,16 +1,174 @@
 /**
  * 
  */
+
+var table = null;
+var pastAppointments = []; 
+var isFromAlignmentPage = false;
+var physNameParamFromAlignments;
 $(document).ready(function() {
 
-	$('.past-appointment-li').on('click', function(){
-		$('.future-appointment-div').css('display','none');
-	});
+	$('li.left-menu-selected').removeClass('left-menu-selected');
+	$('li.past-appointment-li').addClass('left-menu-selected');
+	
+	updateNotificationCounter();
+	
+	getPastAppointments();
+	
+	//Physician name received and parsed for table search
+	var value;
+	if (window.location.search.split('?').length > 1) {
+        var params = window.location.search.split('?')[1].split('&');
+        for (var i = 0; i < params.length; i++) {
+            var key = params[i].split('=')[0];
+            physNameParamFromAlignments = decodeURIComponent(params[i].split('=')[1]);
+            console.log("Name : "+physNameParamFromAlignments);
+            isFromAlignmentPage = true;
+        }
+    }
+	
+});
    
-	$('.left-menu-ul').on('click','li',function(){
-		$('li.left-menu-selected').removeClass('left-menu-selected');
-		$(this).addClass('left-menu-selected');
-		$(this).find('a').addClass('left-menu-selected-anchor');
+var getPastAppointments = function(){
+	console.log("Fetching similar questions");
+	$.ajax({
+		type : 'GET',
+		url : "/getpastappointments",
+		dataType : 'json',
+		success : function(data){
+	    	console.log("Data received (Past Appointments) : "+JSON.stringify(data));
+	    	populatePastAppTable(data);
+	    	pastAppointments =  data;
+		},
+		error : function(e){
+			console.log("Error : "+JSON.stringify(e));
+		}
+	}).done(function(){
+		console.log("ajax complete!");
 	});
 }
-   
\ No newline at end of file
+
+$(document).on('click','button.past-appointment-detail-btn', function(){
+	$('#pastappointment-details-modal').modal('show');
+	var $row = $(this).parent().parent(); 
+	var idx = $(this).attr('id');
+	console.log(" idx : "+idx);
+	
+	$('ul.salesrep-response').html("");
+	$('ul.physician-response').html("");
+	$('div.modal-body-3').html("");
+	
+	if(pastAppointments[idx]["reasonsBySalesRep"].length == 0){
+		$('ul.salesrep-response').append('<li class="meetingexp-salesrep-empty">You did not submit your experience about this meeting</li>');
+		$('li.meetingexp-salesrep-empty').parent().parent().css('background','#EABEBE');
+	}else{
+		for( var i = 0; i< pastAppointments[idx]["reasonsBySalesRep"].length; i++){
+			$('ul.salesrep-response').append(
+					'<li class="sales-rep-response-pointers meeting-exp-li">'+pastAppointments[idx]["reasonsBySalesRep"][i]+'</li>'
+			);
+			
+		}
+		$('li.sales-rep-response-pointers').parent().parent().css('background','aliceblue');
+	}
+	
+	if(pastAppointments[idx]["reasonsByPhysician"].length == 0){
+		$('ul.physician-response').append('<li class="meetingexp-phys-empty">Physician did not submit experience about this meeting</li>');
+		$('li.meetingexp-phys-empty').parent().parent().css('background','#EABEBE');
+	}else{
+		for( var i = 0; i< pastAppointments[idx]["reasonsByPhysician"].length; i++){
+			$('ul.physician-response').append(
+					'<li class="physician-response-pointers meeting-exp-li">'+pastAppointments[idx]["reasonsByPhysician"][i]+'</li>'
+			);
+		}
+		$('li.physician-response-pointers').parent().parent().css('background','aliceblue');
+	}
+	
+	if(pastAppointments[idx]["pitch"] == null) {
+		$('div.modal-body-3').append('<span>You did not upload any pitch for this meeting</span>');
+		$('div.modal-body-3').css('background','#EABEBE');
+	}else{
+		$('div.modal-body-3').append(
+				'<div class="pitch-doc-div" style="display: none;">'+
+					'<object class="pdf-doc-object pdf-doc-object-slidedown" data="'+pastAppointments[idx]["pitch"]["fileLocation"]+'" type="application/pdf"">'+
+						'<embed src="'+pastAppointments[idx]["pitch"]["fileLocation"]+'" alt="pdf" pluginspage="http://www.adobe.com/products/acrobat/readstep2.html">'+
+						'</embed>'+
+					'</object>'+
+				'</div>'
+			);
+		$('div.pitch-doc-div').slideToggle('fast');
+		$('div.modal-body-3').css('background','white');
+	}
+	
+});
+
+var populatePastAppTable = function(appointments){
+	
+	for(var i = 0; i < appointments.length ; i++){
+		console.log(appointments[i]["meetingStatus"]);
+		if(appointments[i]["meetingStatus"] == "LOST"){
+			$('table#past-appointments-table tbody').append(
+					'<tr class="lost-appointment-tr danger">'+
+						'<td style="display:none" class="physician-id">'+appointments[i]["physicianId"]+'</td>'+
+						'<td>'+appointments[i]["physicianName"]+'</td>'+
+						'<td style="display:none" class="product-id">'+appointments[i]["productId"]+'</td>'+
+						'<td>'+appointments[i]["productName"]+'</td>'+
+						'<td>'+appointments[i]["date"]+'</td>'+
+						'<td>'+appointments[i]["meetingStatus"]+'</td>'+
+						'<td class="further-detail-btn">'+
+							'<div class="further-detail-click">'+
+								'<button type="button" id="'+i+'" class="btn btn-default btn-md past-appointment-detail-btn">'+
+									'<span class="glyphicon glyphicon-eye-open" aria-hidden="true"></span>'+
+									'<span class="further-detail-btn-span">View Further Details</span>'+
+								'</button>'+
+							'</div>'+
+						'</td>'+				
+					'</tr>'
+			);
+		}
+		else if(appointments[i]["meetingStatus"] == "PRESCRIBING"){
+			$('table#past-appointments-table tbody').append(
+					'<tr class="prescribing-appointment-tr success">'+
+						'<td style="display:none" class="physician-id">'+appointments[i]["physicianId"]+'</td>'+
+						'<td>'+appointments[i]["physicianName"]+'</td>'+
+						'<td style="display:none" class="product-id">'+appointments[i]["productId"]+'</td>'+
+						'<td>'+appointments[i]["productName"]+'</td>'+
+						'<td>'+appointments[i]["date"]+'</td>'+
+						'<td>'+appointments[i]["meetingStatus"]+'</td>'+
+						'<td class="further-detail-btn">'+
+							'<div class="further-detail-click">'+
+								'<button type="button" id="'+i+'" class="btn btn-default btn-md past-appointment-detail-btn">'+
+									'<span class="glyphicon glyphicon-eye-open" aria-hidden="true"></span>'+
+									'<span class="further-detail-btn-span">View Further Details</span>'+
+								'</button>'+
+							'</div>'+
+						'</td>'+				
+					'</tr>'
+			);
+		}
+		else{
+			$('table#past-appointments-table tbody').append(
+					'<tr class="other-appointment-tr">'+
+						'<td style="display:none" class="physician-id">'+appointments[i]["physicianId"]+'</td>'+
+						'<td>'+appointments[i]["physicianName"]+'</td>'+
+						'<td style="display:none" class="product-id">'+appointments[i]["productId"]+'</td>'+
+						'<td>'+appointments[i]["productName"]+'</td>'+
+						'<td>'+appointments[i]["date"]+'</td>'+
+						'<td>'+appointments[i]["meetingStatus"]+'</td>'+
+						'<td class="further-detail-btn">'+
+							'<div class="further-detail-click">'+
+								'<button type="button" id="'+i+'" class="btn btn-default btn-md past-appointment-detail-btn">'+
+									'<span class="glyphicon glyphicon-eye-open" aria-hidden="true"></span>'+
+									'<span class="further-detail-btn-span">View Further Details</span>'+
+								'</button>'+
+							'</div>'+
+						'</td>'+				
+					'</tr>'
+			);
+		}
+		
+	}
+	table = $('table#past-appointments-table').DataTable();
+	if(isFromAlignmentPage){
+		table.search(physNameParamFromAlignments).draw();
+	}
+}
\ No newline at end of file
diff --git a/src/main/webapp/resources/app/js/products.js b/src/main/webapp/resources/app/js/products.js
index 4f57324..ce1f2cb 100644
--- a/src/main/webapp/resources/app/js/products.js
+++ b/src/main/webapp/resources/app/js/products.js
@@ -11,7 +11,8 @@ $(document).ready(function(){
 	$('li.view-products').addClass('left-menu-selected');
 	
 	updateNotificationCounter();
-	$('.product-selector').select2();
+	
+//	$('.product-selector').select2();
 	
 	$.ajax({
 		type: 'GET',
@@ -49,7 +50,7 @@ $(document).ready(function(){
 			success : function(data){
 		    	productFiles = data;
 		    	console.log("Data received (Product Files): "+JSON.stringify(data));
-		    	createDocsViewEnvironment(data);
+		    	createDocsViewEnvironment(data, currentProductId);
 			},
 			error : function(e){
 				console.log("Error : "+JSON.stringify(e));
@@ -82,9 +83,10 @@ var populateProductSelector = function(products){
 				'</tr>'
 		);
 	}
+	$('#product-selector-id').select2().val('1').trigger("change");
 }
 
-var createDocsViewEnvironment = function(data){
+var createDocsViewEnvironment = function(data, productId){
 	if($('.btn-left-panel').find('.btn-for-product-'+currentProductId).length == 0){
 		$('.btn-left-panel').append(
 				'<div class="btn-container-div-product-'+currentProductId+' btn-container">'+
@@ -100,10 +102,14 @@ var createDocsViewEnvironment = function(data){
 		}
 	attachClickEvent(currentProductId);
 	}
+	var b = $('.btn-for-product-'+productId)[0];
+	$(b).click();
 }
 
 var attachClickEvent = function(productId){
 	$(document).on('click','button.btn-for-product-'+productId,function(){
+		$('button.show-doc').removeClass('product-doc-button-clicked');
+		$(this).addClass('product-doc-button-clicked');
 		$('.doc-middle-panel').css('display','none');
 		$('.update-right-panel').css('display','none');
 		$('.analysis-right-panel').css('display','none');
diff --git a/src/main/webapp/resources/app/js/showalignments.js b/src/main/webapp/resources/app/js/showalignments.js
index aa8992c..7cf943f 100644
--- a/src/main/webapp/resources/app/js/showalignments.js
+++ b/src/main/webapp/resources/app/js/showalignments.js
@@ -10,11 +10,15 @@ var averageTravelTime = 30; //minutes
  */
 $(document).ready(function() {
    var table = $('#aligned-physician-table').DataTable({
-	   order: [[16, "desc"]]
+	   order: [[0, "desc"]]
    });
+   /*,
+	   "oSearch": {"sSearch": "O_Med_2"}
+   });*/
+   console.log("Alignment referrer : "+document.referrer);
+   
     $('#aligned-physician-table tbody').on( 'click', 'tr', function (e) {
     	var cell = $(e.target).get(0);
-    	console.log(cell.nodeName);
     	if(cell.childElementCount < 1 && cell.nodeName != 'INPUT' && cell.nodeName != 'SPAN' && cell.nodeName != 'TEXTAREA' ){
 	    	$(this).toggleClass('selected');
 	    	if ( $(this).hasClass('selected') ) {
@@ -52,6 +56,20 @@ $(document).ready(function() {
     updateNotificationCounter();
 });	
 
+$(document).on('click','button.redirect-past-appointments',function(){
+	   var name = $(this).parent().parent().find('td.physician-name').html();
+	   window.location.replace("/pastappointments?param="+name);
+});
+	
+$('.show-contact').click(function(){
+	$(this).parent().parent().find('div.aligned-physician-contact').toggle();
+	if($(this).parent().parent().find('div.aligned-physician-contact').css('display') == 'none'){
+	    $(this).find('span.button-value').html("Show Contact");
+	}else if($(this).parent().parent().find('div.aligned-physician-contact').css('display') == 'block'){
+	    $(this).find('span.button-value').html("Hide Contact");
+	}
+});
+
 /**
  * Set color of the row based on the 
  * importance factor of corresponding physician
@@ -100,10 +118,8 @@ $('.submit-selected-alignments').click(function(){
 				additionalNotesList.push(additionalNotes);
 			}
 		}
-		$(this).find('td').each(function(idx, valTD){
-			if(idx == 0) physIds.push($(valTD).html());
-			if(idx == 10) productIds.push($(valTD).html());		//Picking product for selected alignments
-		});
+		physIds.push($(val).find('td.physician-id').html());
+		productIds.push($(val).find('td.product-id').html());
 	});
 	if(!isDataInvalid){
 		fixAppointments(physIds, appointStartTimeList,appointEndTimeList, productIds, appointDateList, appointStatusList, additionalNotesList);
diff --git a/src/main/webapp/resources/app/js/showappointments.js b/src/main/webapp/resources/app/js/showappointments.js
index ab144de..36211e3 100644
--- a/src/main/webapp/resources/app/js/showappointments.js
+++ b/src/main/webapp/resources/app/js/showappointments.js
@@ -6,6 +6,9 @@ var tableAppointment = null;
 var currentSelectedAppointment = 0;
 var averageTravelTime = 30; //minutes
 $(document).ready(function() {
+	$('li.left-menu-selected').removeClass('left-menu-selected');
+	$('li.today-appointment-li').addClass('left-menu-selected');
+	
 	$('.slidedown-alignments').click(function(){
 		    $('.slidedown-alignments-show').slideToggle('fast');
 	});
@@ -38,23 +41,23 @@ $(document).ready(function() {
 	
    updateNotificationCounter();
    
-   $('.today-appointment-li').on('click', function(){
-	   $('.future-appointment-div').css('display','none');
-	   $('.today-appointment-div').css('display','block');
-   });
-   
-   $('.future-appointment-li').on('click', function(){
-	   $('.today-appointment-div').css('display','none');
-	   $('.future-appointment-div').css('display','block');
-   });
-   
-   $('.left-menu-ul').on('click','li',function(){
-	   $('li.left-menu-selected').removeClass('left-menu-selected');
-	   $(this).addClass('left-menu-selected');
-	   $(this).find('a').addClass('left-menu-selected-anchor');
-   });
-   
-   $( ".today-appointment-li" ).trigger( "click" );
+//   $('.today-appointment-li').on('click', function(){
+//	   $('.future-appointment-div').css('display','none');
+//	   $('.today-appointment-div').css('display','block');
+//   });
+//   
+//   $('.future-appointment-li').on('click', function(){
+//	   $('.today-appointment-div').css('display','none');
+//	   $('.future-appointment-div').css('display','block');
+//   });
+//   
+//   $('.left-menu-ul').on('click','li',function(){
+//	   $('li.left-menu-selected').removeClass('left-menu-selected');
+//	   $(this).addClass('left-menu-selected');
+//	   $(this).find('a').addClass('left-menu-selected-anchor');
+//   });
+//   
+//   $( ".today-appointment-li" ).trigger( "click" );
 	   
    /**
     * Toggles between selected and de-selected rows of the table
@@ -274,10 +277,8 @@ $('.submit-selected-alignments').click(function(){
 				additionalNotesList.push(additionalNotes);
 			}
 		}
-			$(this).find('td').each(function(idx, valTD){
-				if(idx == 0) physIds.push($(valTD).html());
-				if(idx == 10) productIds.push($(valTD).html());		//Picking product for selected alignments
-			});
+		physIds.push($(val).find('td.physician-id').html());
+		productIds.push($(val).find('td.product-id').html());
 	});
 	
 	if(!isDataInvalid){
@@ -459,10 +460,8 @@ $('.submit-selected-followup-alignments').click(function(){
 				appointmentIdList.push(appointId);
 			}
 		}
-			$(this).find('td').each(function(idx, valTD){
-				if(idx == 0) physIds.push($(valTD).html());
-				if(idx == 10) productIds.push($(valTD).html());		//Picking product for selected alignments
-			});
+		physIds.push($(val).find('td.physician-id').html());
+		productIds.push($(val).find('td.product-id').html());
 	});
 	
 	if(!isDataInvalid){
@@ -520,8 +519,9 @@ var fixFollowupAppointments = function(physIds, appointStartTimeList, appointEnd
 var addMeetingUpdate = function(){
 	
 	var appointmentId = currentSelectedAppointment;//tableAppointment.row('.selected').data()[0];												//Getting Appointment id
-	var physicianId = tableAppointment.row('.selected').data()[1];													//Getting Physician id
-	var productName = tableAppointment.row('.selected').data()[tableAppointment.row('.selected').data().length-4];	//Getting product name
+	var physicianId = $('tr.selected').find('td.physician-id').html();
+	var product_td = $('table#appointment-fixed-physician-table').find('tr.selected').find('td.product-name-td')[0]
+	var productName =  product_td.textContent;
 	
 	var formData = {};
 	
diff --git a/src/main/webapp/resources/docs/edetailing/D_Med_3.pdf b/src/main/webapp/resources/docs/edetailing/D_Med_3.pdf
new file mode 100644
index 0000000..2a183d5
--- /dev/null
+++ b/src/main/webapp/resources/docs/edetailing/D_Med_3.pdf
@@ -0,0 +1,1501 @@
+                                    CIH-1
+
+ADCETRIS™
+Brentuximab Vedotin
+
+CD30-Directed Therapy for
+Hodgkin Lymphoma
+
+Oncologic Drugs Advisory Committee
+
+July 14, 2011
+                                                                                           CIH-2
+
+Brentuximab Vedotin
+Hodgkin Lymphoma
+Introduction
+
+Elaine Waller, PharmD
+
+Senior Vice President of Regulatory Affairs
+Seattle Genetics
+                                                                                              CIH-3
+
+Brentuximab Vedotin Targets CD30 Antigen
+
+Transmembrane glycoprotein receptor,
+  member of TNF receptor superfamily
+
+Leads to transduction of biologic signals,
+  including cell proliferation
+
+Highly expressed on HL and ALCL cells
+Restricted distribution on normal cells:
+
+   – Expressed on activated lymphocytes
+      (B cell, T cell, NK cell)
+
+   – Weakly expressed on activated monocytes
+                                                                         CIH-4
+
+CD30+ Lymphomas
+
+                                 Lymphoma  Non-Hodgkin lymphoma
+Hodgkin lymphoma
+
+B-cell neoplasms                           T-cell & NK-cell neoplasms
+
+                  Peripheral T-cell lymphoma &                   Cutaneous TCL
+                  Natural killer T-cell lymphoma
+
+                                           PTCL not otherwise specified
+
+                                           Systemic anaplastic large cell lymphoma
+
+                                           Angio-immunoblastic TCL
+
+                                           Other PTCLs
+Comparison of Unconjugated CD30 mAb CIH-5
+With Brentuximab Vedotin
+Hodgkin Lymphoma
+
+Dose             CD30 mAb                                 Brentuximab vedotin
+               (unconjugated                              (conjugated cAC10)
+Patients, n
+Objective           cAC10)                                        1.8 mg/kg
+response rate  6 or 12 mg/kg                                  every 3 weeks
+Complete
+remissions          weekly                                            102
+                       38                                             75%
+                        —
+                                                                      34%
+                       —
+
+Forero-Torres A, et al. Br J Haematol. 2009;146:171-179.
+                                                                                                             CIH-6
+
+Brentuximab Vedotin Structure
+
+Antibody                             Linker                                      Drug
+
+cAC10 anti-CD30 Attachment                 Protease-                             MMAE
+                                                                           cytotoxic agent
+antibody  group                      cleavage site
+
+                                  O  O          H  O              O     H  O               N            HO
+          S                             N       N     N        ON       N     N  OCH3O                    N
+                                        H    O        H              O                                    H
+                              N
+                        O                                                                     OCH3O
+
+                                                        NH
+                                                   O
+
+                                                          NH2
+                                                                                              CIH-7
+
+Brentuximab Vedotin Is More Active Than
+MMAE Alone
+
+Tumor volume, mm3  1200
+
+                   1000
+
+                   800
+
+                   600
+
+                   400
+
+                   200
+
+                   0
+                      0 20 40 60 80 100 120
+
+                                                  Days
+
+Untreated (0/5 DR)        Control ADC 2 mg/kg (0/5 DR)
+MMAE 0.25 mg/kg (0/5 DR)  Brentuximab vedotin 2 mg/kg (4/5 DR)
+
+DR = Durable response.
+HL L428 subcutaneous xenograft model in NSG mice (n = 5 group), mean ± SD, q4dx3.
+                                                                                                         CIH-8
+
+Brentuximab Vedotin
+Mechanism of Action
+
+                                                        1. ADC binds to CD30
+
+2. ADC-CD30 complex is  CD30
+internalized and
+trafficks to lysosome
+
+3. MMAE is
+released
+
+                                                                              6. Apoptosis (cell death)
+
+4. MMAE binds           5. G2/M cell
+tubulin and             cycle arrest
+prevents microtubule
+assembly
+                         CIH-9
+
+Proposed Indication and
+Dosage Regimen
+
+Brentuximab vedotin is a CD30-directed
+  antibody-drug conjugate indicated for the
+  treatment of patients with relapsed or
+  refractory Hodgkin lymphoma
+
+Brentuximab vedotin 1.8 mg/kg administered
+  as an IV infusion over 30 minutes every
+  3 weeks
+
+Treat until disease progression or
+  unacceptable toxicity
+                                          CIH-10
+
+Brentuximab Vedotin in Patients With
+Hodgkin Lymphoma
+
+ Efficacy
+   – Clinically relevant objective
+      response rates
+   – Durable complete remissions
+   – Resolution of disease-related signs
+      and symptoms
+
+ Safety
+   – Most common AEs were grade 1 and 2
+   – Peripheral neuropathy is manageable
+                                                                                         CIH-11
+
+Clinical Trials Submitted in BLA
+
+   IND             EOP1 Phase 2 Clin Pharm        Clinical  BLA
+submitted        meeting SPA meeting              pre-BLA   submission
+                                                  meeting   Feb
+   Jun                Jul Jan Mar
+                                                       Nov
+
+2006       2007  2008          2009         2010            2011
+
+                 Phase 1 q3wk
+
+                               Phase 1 q1wk
+                                              Pivotal HL study
+
+                                             Pivotal ALCL study
+                                                                 QTc
+
+                                                           Excretion
+                                                              DDI
+                                                                    Special populations
+                                                                                            CIH-12
+
+Special Protocol Assessment
+
+ Agreements made with the FDA
+    – Primary endpoint
+
+          • ORR per independent review facility (IRF)
+          • 2007 Revised Response Criteria for Malignant Lymphoma
+
+    – ORR of 30% considered a meaningful response
+    – Supporting evidence
+
+          • Duration of response
+          • Complete remission
+          • B symptom resolution
+          • Investigator assessment vs IRF concordance
+
+ SPA remains in effect
+                                                                                            CIH-13
+
+AETHERA: Phase 3 HL Post-ASCT
+
+ Randomized, double-blind, placebo-controlled, multicenter,
+    phase 3 clinical trial
+
+ Patients randomized 1:1 to receive brentuximab vedotin or
+    placebo every three weeks
+
+ Efficacy endpoints
+     – Primary: Progression-free survival per IRF
+     – Key Secondary: Overall survival
+
+ Population (N = 322) includes at least one of the following
+     – Refractory to front-line therapy
+     – Relapsed within 12 months
+     – Extranodal disease
+
+ Stratified by response to frontline and salvage treatments
+                                 CIH-14
+
+Ongoing Clinical Development in
+Hodgkin Lymphoma
+
+ AETHERA - Phase 3 trial in patients at high risk
+   of residual HL following autologous SCT
+
+ Phase 1 trial in front-line HL
+
+ Expanded access program in relapsed or
+   refractory HL and systemic ALCL
+                                                        CIH-15
+
+Today’s Agenda
+
+Introduction          Elaine Waller, PharmD
+                      Seattle Genetics
+
+CD30-Directed Therapy for Joseph M. Connors, MD, FRCPC
+
+Hodgkin Lymphoma      British Columbia Cancer Agency
+
+Brentuximab Vedotin   Eric Sievers, MD
+Hodgkin Lymphoma      Seattle Genetics
+Efficacy Profile
+
+Brentuximab Vedotin   Tom Reynolds, MD, PhD
+Safety Profile        Seattle Genetics
+
+Hodgkin Lymphoma      Joseph M. Connors, MD, FRCPC
+Benefit:Risk Profile  British Columbia Cancer Agency
+                                                              CIH-16
+
+Consultants
+
+ David R. Cornblath, MD          J. Michael O’Neal, MD
+    Professor, Neurology             Chief Medical Officer
+    Johns Hopkins University         CoreLab Partners
+
+ L. Jeffrey Medeiros, MD         Barbara Pro, MD
+    Professor, Chair, Dept of        Associate Professor
+    Hematopathology                  Fox Chase Cancer Center
+    MD Anderson Cancer Center
+
+ Owen O’Connor, MD
+    Deputy Director of Clinical
+    Research and
+    Cancer Treatment
+    New York University Cancer
+    Institute
+                                                                                          CDH-1
+
+Brentuximab Vedotin
+CD30 Directed Therapy for
+Hodgkin Lymphoma
+
+Joseph M. Connors, MD, FRCPC
+
+Clinical Director, Centre for Lymphoid Cancer
+British Columbia Cancer Agency
+University of British Columbia
+                                                                                   CDH-2
+
+Disclosures
+
+                          Not-for-profit Sources               For-profit Sources
+
+Institutional       Canadian Cancer Society Research     Amgen              Bayer Healthcare
+research support    Institute                            Cephalon           Lilly
+including clinical  NCI of Canada Clinical Trials Group  Genentech          Merck
+trials              Terry Fox Foundation                 Hoffmann-La Roche  Roche Canada
+                    SWOG                                 Johnson & Johnson  Seattle Genetics
+Advisory
+Board/Committee     ASH                                  None
+                    ASCO
+Employee            Lymphoma Foundation Canada
+Speakers’ Bureau    Lymphoma Research Foundation (US)
+Honoraria           NCIC Canada
+Board member
+Paid consultant     British Columbia Cancer Agency       None
+Stockholder
+                    ASH                                  None
+
+                    ASH, ASCO                            None
+
+                    None                                 None
+
+                    None                                 None
+
+                    None                                 None
+
+                                                                            July 2011
+                                                                                            CDH-3
+
+CD30: Optimal Target for Antibody-Drug
+Conjugate Therapy
+
+Highly restricted normal cell surface
+  expression
+
+Defining marker for Hodgkin lymphoma—
+  malignant Hodgkin Reed-Sternberg cells
+
+Standard immunohistochemical test
+
+   – Widely available
+
+   – Reliable and reproducible
+                                                                                 CDH-4
+
+Hodgkin Reed-Sternberg Cells
+Strongly Express CD30
+
+                                                                       CD30+
+                                                                       HRS cell
+
+Cytokine receptor CD30 selectively
+         expressed in HRS cells
+                                                                                                 CDH-5
+
+  Hodgkin Lymphoma
+
+    2010 estimatesa
+       – 8490 new cases of HL were diagnosed
+       – 1320 patients would die from their disease
+
+    Median age at diagnosis is 38 yearsb
+       – 90% of patients < 60 years
+
+    Clinical presentation
+       – Painless, enlarged lymph nodes commonly in
+          the neck and thorax
+       – 15% of patients with B symptoms (fever,
+          night sweats, weight loss > 10%)
+
+a Jemal A, et al. CA Cancer J. 2010;60(5):277-300; b National Cancer Institute. 2010. Surveillance, Epidemiology, and
+End Results (SEER) Program SEER*Stat Database: Incidence. http://seer.cancer.gov/canques/incidence.html.
+Progression-Free Survival by                                                            CDH-6
+Decade of Diagnosis
+
+Hodgkin Lymphoma
+
+         1.0                                      N = 3216
+         0.8
+         0.6                 Cumulative survival  2000s  1990s, bone marrow transplantation
+         0.4
+         0.2                                                          1980s, ABVD
+
+            0                                                                        1970s, wide field
+               0                                                                     radiation and MOPP-
+                                                                                     type chemotherapy
+Data courtesy of Dr. Connors.
+                                                                                        1960s
+
+                                                  10 20 30                          40
+                                                  Progression-free survival, years
+                                                                                            CDH-7
+
+Treatment Algorithm for Advanced-Stage
+Hodgkin Lymphoma
+
+First-line   Multi-agent     ABVD or Stanford V or BEACOPP                           Current
+treatment   chemotherapy                                                           unmet need
+
+                  70% cured  ± RT                             30% Progressive
+                                                              disease or relapse
+Second-line                  Combination chemotherapy                              30%
+treatment                        (eg, DHAP, ICE, GVD)            30% < CR/PR
+(including ASCT)
+                                       70% CR/PR
+
+                                                              No standard of care
+
+                                 High-dose therapy with
+                             autologous stem cell transplant
+
+Post-ASCT         50% cured                                   50% Progressive      50%
+                                                              disease or relapse
+
+ASCT = Autologous stem cell transplant; CR = Complete remission; PR = Partial remission; RT = Radiation therapy.
+                                                                                                CDH-8
+
+Poor Survival in HL Patients Who
+Relapse After a Stem Cell Transplant
+
+Overall survival in patients who relapse post-ASCT (N = 756)
+   100
+
+                80
+
+Probability, %  60
+
+                                 Median = 2.4 yr
+
+                40
+
+                20
+
+                     0
+                        0 5 10 15 20
+
+                                                       Time from relapse, yr
+
+Horning et al. 10th International Conference on Malignant Lymphoma; Lugano, Switzerland; 2008.
+72% of Relapses After ASCT Occur in CDH-9
+the First 12 Months and Have a Very
+Poor Prognosis
+
+                100 1-yr mortality 40%
+
+                    TTR, mo N % Median OS, yr
+
+                80  > 12 214 28                                            4.6
+
+Probability, %      0 - 12 542 72                                          1.2
+
+                60
+
+                40 N = 756
+                                                                p < 0.001
+
+                20
+
+                     0
+
+                        0 5 10 15 20
+
+                                                       Time from relapse, yr
+
+TTR = Time to relapse.
+Horning et al. 10th International Conference on Malignant Lymphoma; Lugano, Switzerland; 2008.
+                                                                                           CDH-10
+
+Treatment Options After Failure of ASCT
+
+No reliably curative options
+   – Experimental allogeneic SCT
+       • Applicable to small minority
+       • Associated with marked toxicity
+   – Curative wide-field radiation applicable
+      to < 5%
+
+No approved treatment
+Pronounced unmet need
+                                                                              CDH-11
+
+Treatment of Relapsed or Refractory
+Hodgkin Lymphoma
+
+                               All patients               Post-ASCT patients
+
+Agent             Evaluable                                        Evaluable
+Vinblastinea      patients, n  ORR, n (%) CR, n (%) patients, n ORR, n (%) CR, n (%)
+Vinorelbinea
+Rituximaba        17           10 (59)       2 (12)  17   10 (59)             2 (12)
+Gemcitabinea
+Vinorelbine +     22           11 (50)       3 (14)
+Gemcitabinea
+Rituximab +       22           5 (23)        1 (5)   18   5 (23)              1 (5)
+Gemcitabinea
+Bortezomiba       27           6 (22)        0       16 5 (31) 0
+Bortezomiba
+Bortezomiba       8            6 (75)        4 (50)
+
+Gem, Vinor, Doxb  33           16 (48)       5 (15)  18   11 (61)
+Panobinostatc
+                  14           1 (7)         0       14   1 (7)                                                 0
+
+                  30 0 0 28
+
+                  12 0 0
+
+                  88           62 (70) 17 (19)       36   27 (75) 6 (17)
+
+                  129          35 (27)       5 (4)   129  35 (27)             5 (4)
+
+a Crump M. Hema Am Soc Hematol Educ Prog. 2008:326-333; b Bartlett NL, et al. Ann Oncol. 2007;18(6):1071-1079;
+c Sureda A, et al. 52nd ASH Annual Meeting and Exposition. 2010. Abstract 169.
+                                                                                           CDH-12
+
+Key Concepts for Patients With Relapsed
+or Refractory Hodgkin Lymphoma
+
+Background                                            Hodgkin
+• Malignant cells express CD30                       lymphoma
+Disease impact
+• Not cured with current standard treatments          ~ 100 %
+• Median OS
+                                                        ~ 25%
+  – After failure of autologous transplant
+  – Post-ASCT failure in < 1 year                       29 mo
+• Typical response to available treatment = partial     14 mo
+• Typical duration of response                       20% - 60%
+                                                      3 - 12 mo
+                                                                                          CEH-1
+
+Brentuximab Vedotin Treatment of
+Patients With Hodgkin Lymphoma
+
+Eric Sievers, MD
+
+Vice President of Clinical Affairs
+Seattle Genetics
+                                                                                    CEH-2
+
+Brentuximab Vedotin Clinical
+Development Program
+
+2006  2007  2008          2009  2010  2011
+
+            Phase 1 q3wk
+
+                          Phase 1 q1wk
+                                         Pivotal HL study
+
+                                        Pivotal ALCL study
+                                                            QTc
+
+                                                      Excretion
+                                                         DDI
+                                                               Special populations
+                                                                                                 CEH-3
+
+  Phase 1 First-in-Human Study
+
+      Phase 1 dose-escalation study of brentuximab vedotin in patients with
+         relapsed or refractory CD30+ hematological malignancies
+
+      N = 45 enrolled at 4 US sites
+           – Median age of 36 years
+           – HL (n = 42), sALCL (n = 2), and angioimmunoblastic T-cell
+               lymphoma (n = 1)
+           – Median 3 prior regimens; prior ASCT in 73%
+
+      Brentuximab vedotin was given intravenously every 3 weeks in
+         escalating doses ranging from 0.1 to 3.6 mg/kg in successive cohorts
+
+      1.8 mg/kg every 3 weeks
+           – Defined as MTD; also reasonably well-tolerated over months of
+               continued therapy
+           – Obtained durable complete remissions
+           – Employed in the subsequent, paired registrational trials
+
+a Younes A, et al. N Engl J Med. 2010;363(19):1812-1821.
+                                                    CEH-4
+
+Results
+
+Phase 1 Program—Hodgkin Lymphoma
+
+Overall response rate                 Q 3 week        Q 1 week
+    Complete remission rate               trial           trial
+
+Median, months (min - max)              n = 42          n = 38
+    Duration of overall response          36%             53%
+                                          21%             26%
+    Duration of complete remission
+                                           NE              4.8
+                                    (0.6 - 19.4+)   (0.5+ - 17.3+)
+
+                                           NE              5.1
+                                    (1.4+ - 19.4+)  (0.5+ - 17.3+)
+                                                                                    CEH-5
+
+Brentuximab Vedotin Clinical
+Development Program
+
+2006  2007  2008          2009  2010  2011
+
+            Phase 1 q3wk
+
+                          Phase 1 q1wk
+                                         Pivotal HL study
+
+                                        Pivotal ALCL study
+                                                            QTc
+
+                                                      Excretion
+                                                         DDI
+                                                               Special populations
+                                                                                                          CEH-6
+
+Phase 2 Pivotal, Multicenter,
+Open-Label Trial Endpoints
+
+ Primary: Overall objective response rate (CR + PR)
+
+– Independent review facility
+
+– Revised response criteria for malignant
+  lymphomaa
+
+ Secondary
+
+– Efficacy   – Safety
+
+• Duration of response • Adverse events
+
+• CR rate                      • Laboratory
+
+• PFS                          abnormalities
+
+• OS
+
+• B symptom resolution
+
+CR = Complete remission; PR = Partial remission; PFS = Progression-free survival; OS = Overall survival.
+a Cheson BD, et al. J Clin Oncol. 2007;25(5):579-586.
+                                                                                                 CEH-7
+
+2007 Revised Response Criteria for
+Malignant Lymphoma
+
+Response  Definition               Nodal lesions
+CR
+PR        Disappearance of all     Residual mass of any size
+          evidence of disease      permitted if PET-negative
+SD
+          Regression of            ≥ 50% decrease in SPD of index
+PD
+          measurable disease and lesions; 1 or more PET-positive at
+
+          no new sites             previously involved site
+
+          Failure to attain CR/PR  PET-positive at previously
+          or PD                    involved site and no new sites
+                                   of disease
+
+          Any new lesion or        Progression of existing non-index
+          increase by ≥ 50% of     lesions or ≥ 50% increase in SPD
+          previously involved      of index lesions or new lesion
+
+          sites from nadir         > 1.5 cm in any axis
+
+CR = Complete remission; PR = Partial remission; SD = Stable disease; PD = Progressive disease;
+SPD = Sum of the products of the diameters.
+Cheson BD, et al. J Clin Oncol. 2007;25(5):579-586.
+                                                                                             CEH-8
+
+Pivotal, Multicenter, Open-Label Trials of
+Brentuximab Vedotin
+
+     Brentuximab vedotin 1.8 mg/kg IV over 30 minutes every 3 weeks
+
+S  E Follow-up
+C
+R  N every
+E
+E  R 12 weeks
+N
+I  O
+N
+G  L
+
+   L 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
+   M
+   E  Cycle
+
+   N
+
+   T
+
+   CT scan between Days 15 and 21 of cycle
+   PET scan (no additional scans past Cycle 7 unless clinically indicated)
+                                           CEH-9
+
+Key Eligibility Criteria
+
+Hodgkin Lymphoma
+
+Relapsed or refractory, progressive HL
+CD30 expression confirmed centrally
+FDG-avid, CT-measurable disease ≥ 1.5 cm
+Prior ASCT was required
+Age ≥ 12 years
+ECOG performance status score 0 to 1
+                              CEH-10
+
+Statistical Considerations
+
+Hodgkin Lymphoma
+
+Trial and analyses conducted under Special
+  Protocol Assessment
+
+Primary statistical hypothesis: ORR 95% CI
+  lower bound > 20%
+
+   – Study size of 100 patients was chosen to
+      allow evaluation of primary hypothesis
+
+   – Observation of an ORR of 29% or greater
+      would exclude a lower bound of 20%
+
+ORR = Overall response rate.
+                             CEH-11
+
+Study Conduct and Oversight
+
+Hodgkin Lymphoma
+
+Study steering committee guided design,
+  conduct, and data interpretation
+
+Independent data monitoring committee
+  actively evaluated for safety signals
+
+Independent response assessments
+
+   – Prospectively rendered by central
+      radiology blinded to clinical data
+
+   – Overall assessment additionally integrated
+      clinical data
+Demographics and                                            CEH-12
+Baseline Characteristics
+                                                   N = 102
+ Hodgkin Lymphoma                               31 (15 - 77)
+                                                48 M / 54 F
+Median age, yr (range)
+Gender, n                                              41
+ECOG performance status score, %                       59
+                                                       71
+    0                                                  42
+    1                                           3.5 (1 - 13)
+Refractory to front-line therapy, %                    66
+Refractory to most recent treatment, %               100
+Median prior chemotherapy regimens, n (range)          71
+Prior radiation, %                              6.7 (0 - 131)
+Prior ASCT, %
+Relapsed ≤ 1 yr post-ASCT, %
+Median time from ASCT to first post-transplant
+relapse, months (range)
+  Response Results                                                                            CEH-13
+
+   Hodgkin Lymphoma                                                      N = 102
+                                                                       75 (65, 83)
+       Overall response rate, % (95% CI)                               34 (24, 44)
+           Complete remission, % (95% CI)
+           Partial remission, %                                              40
+
+       Median, months (95% CI)                                       6.7 (3.6, 14.8)
+           Duration of overall response                              20.5 (10.8, NE)
+           Duration of complete remission
+           Progression-free survival                                  5.6 (5.0, 9.0)
+           Overall survivala                                         22.4 (21.7, NE)
+
+       B-symptom resolution, % (n/N)                                   77% (27/35)
+
+NE = Not estimable.
+a 18-month overall survival estimated to be 80% (95% CI: 73%, 88%).
+                                                                          CEH-14
+
+Maximum Tumor Reduction
+
+Hodgkin Lymphoma
+
+94% (96 of 102)a of patients achieved tumor reduction
+
+a 4 patients not included in analysis (3, no measurable lesions per IRF;
+1, no post-baseline scans).
+                                                                                           CEH-15
+
+PFS by Best Clinical Response per IRF
+
+Hodgkin Lymphoma
+
+N Median, mo
+
+CR 35 21.7
+
+PR 41  5.1
+
+SD 22  3.5
+
+PD 3   1.2
+                                                                                           CEH-16
+
+CR Rate Was Similar in All Patient Subsets
+
+Hodgkin Lymphoma
+
+Subgroups                                      Overall CR rate = 34%  CR / N
+Overall                                                               35 / 102
+Primary refractory    Yes                                             26 / 72
+                      No
+Time to relapse       ≤ 1 yr                                            9 / 30
+post-ASCT             > 1 yr                                          18 / 72
+Baseline B symptoms   Yes                                             17 / 30
+present               No                                              10 / 35
+Baseline ECOG         0                                               25 / 67
+                      1                                               19 / 42
+Baseline SPD per IRF  ≤ 5 cm2                                         16 / 60
+                      > 5 and ≤ 10 cm2
+                      > 10 cm2                                          3 / 11
+                                                                        9 / 11
+                                                                      22 / 77
+Overall Survival                                            CEH-17
+                  89% estimated 12-month OS
+Hodgkin Lymphoma
+                                                                                           CEH-18
+
+Consistent Response Rates
+
+Pivotal Studies in Two CD30+ Lymphomas
+
+Treatment response                    HL patients  ALCL patients
+  Overall response rate, % (95% CI)     N = 102         N = 58
+
+ Complete remission, % (95% CI)             75             86
+                                         (65, 83)       (75, 94)
+  Median duration of response for CR
+  patients, mo (95% CI)                     34             57
+                                         (25, 44)       (43, 70)
+
+                                           20.5           13.2
+                                       (10.8, NE)     (10.8, NE)
+
+NE = Not estimable.
+Change in tumor size from baseline %                                                                                           CEH-19
+
+                                    Consistent Tumor Reduction
+
+                                    Pivotal Studies in Two CD30+ Lymphomas
+
+                                                                                                                                                       HL
+
+                                                                                                                                     Systemic ALCL
+                                                                                           CEH-20
+
+Durable Complete Remission Represents
+Clinical Benefit in CD30+ Lymphoma Patients
+
+                                      CD30+ lymphomas
+
+           Hodgkin                       Systemic ALCL
+          lymphoma
+
+Q3 week    Weekly        Pivotal study         Pivotal study
+  N = 42    N = 38           N = 102                N = 58
+          ORR 53%           ORR 75%
+ORR 36%    CR 26%            CR 34%,             ORR 86%
+ CR 21%                                           CR 57%,
+                    median CR = 20.5 mo  median CR = 13.2 mo
+                       CSH-1
+
+Brentuximab Vedotin
+Safety Profile
+
+Tom Reynolds, MD, PhD
+
+Chief Medical Officer
+Seattle Genetics
+                                             CSH-2
+
+Safety Profile of Brentuximab Vedotin
+
+        Phase 2
+Safety and efficacy
+
+HL pivotal  ALCL pivotal
+ (n = 102)     (n = 58)
+
+Total Phase 2: N = 160      Total number of
+                           patients exposed
+          Phase 1
+           Safety             in completed
+                                  studies
+Q 3 week    Q 1 week
+ (n = 45)    (n = 44)             N = 357
+
+Clinical pharmacology
+
+  QTc       DDI/excretion
+(n = 52)        (n = 56)
+                                                      CSH-3
+
+Brentuximab Vedotin Exposure
+
+Median treatment                     HL patients      Total patients
+Cycles, n (range)                       n = 102           N = 160
+Duration, mo (range)
+Relative dose intensity, % (range)    9.0 (1 - 16)      7.0 (1 - 16)
+                                    6.2 (0.7 - 12.9)  5.5 (0.7 - 12.9)
+                                    96.0 (69 - 107)   97.3 (47 - 115)
+                                                     CSH-4
+
+Dose Modifications
+
+ Dose modifications were prospectively defined in
+   study protocols
+
+ Patients could have their dose delayed up to
+   3 weeks or reduced to 1.2 mg/kg for AEs
+
+Per-protocol and unplanned                               Patients, %
+dose modifications                                      HL Total
+Dose reduction                                       n = 102 N = 160
+Dose delaya                                             11 10
+Dose adjustment due to an AE                            47 41
+                                                        12 8
+
+a Only 8% of total doses were delayed due to an AE.
+                                          CSH-5
+
+Patient Disposition
+
+                     HL patients, N  102
+Enrolled, n                          102
+Received ≥ 1 dose, n
+
+Reason for treatment discontinuation, %
+
+Completed treatment                  18
+
+Progressive disease                  44
+
+Adverse event                        20
+
+Investigator decision                12
+
+Patient decision, non-AE             7
+                                                                                             CSH-6
+
+Adverse Events of Any Relationship
+Occurring in ≥ 20% of Phase 2 Patients
+
+                                        Patients, %
+
+Preferred term                             HL     Total
+Peripheral sensory neuropathy           n = 102  N = 160
+Fatigue
+Nausea                                  47 44
+Diarrhea
+Pyrexia                                 46 42
+Upper respiratory tract infection
+Neutropenia                             42 41
+Vomiting
+                                        36 34
+
+                                        29 31
+
+                                        37 28
+
+                                        22 21
+
+                                        22 20
+
+a Only 8% of total doses were delayed.
+                                                                                             CSH-7
+
+Adverse Events Grade 3-4 Occurring in
+≥ 2% of Phase 2 Patients
+
+                    HL patients, %         Total patients, %
+                         n = 102                 N = 160
+
+Preferred term       Any                    Any
+Peripheral sensory  grade Grade 3 Grade 4  grade Grade 3 Grade 4
+neuropathy
+Fatigue             47 8            —      44 9  —
+Diarrhea
+Pyrexia             46 2            — 42   2     1
+Neutropenia         36 1                         —
+Thrombocytopenia    29 2            — 34   2     —
+Peripheral motor    22 14                        7
+neuropathy          86              — 31   2     3
+                    12 1                         —
+                                    6 21 13
+
+                                    2 10 7
+
+                                    —9 2
+
+Total patients with any ≥ Grade 3 event = 55%
+Summary of Deaths                                           CSH-8
+
+All deaths                           Patients, n
+   Related to disease               HL Total
+   Not related to disease        n = 102 N = 160
+   Disease relationship unknown     13 25
+                                    10 18
+Deaths < 30 days of last dose
+                                      25
+                                      12
+                                     —6
+                           CSH-9
+
+Special Safety Topics and
+Management of Toxicity
+                                                                           CSH-10
+
+Peripheral Neuropathy AEs
+
+                                                        HL patients, %  Total patients, %
+                                                             n = 102          N = 160
+
+                                                        Any grade Grade 3 Any grade Grade 3
+
+Any PN SMQ AEa                                          55 11 53 11
+
+Peripheral sensory neuropathy                           47  8 44           9
+
+Peripheral motor neuropathy                             12  1           9  2
+
+Paresthesia                                             4—4—
+
+Demyelinating polyneuropathy                            2   2           1  1
+
+Hypoesthesia                                            2—1—
+
+Muscular weakness                                       2111
+
+Neuralgia                                               —— 1 —
+
+SMQ = Standard MedDRA query.
+a Events of any relationship occurring in > 1 patient.
+                                                                                           CSH-11
+
+Characterization of Treatment-Emergent
+Peripheral Neuropathy
+
+Total Phase 2 Population
+
+                                          Weeks to onset
+0 12 24 36 48
+
+  Any PN       Grade 2 PN Grade 3 PN
+  (n = 84)
+   12 wk       (n = 41) (n = 18)
+(0.1 - 41.3)
+               24 wk  33 wk
+
+               (0.1 - 51.9) (6.0 - 57.1)
+
+ Median time to complete or partial resolution: 6.6 wk (0.3, 54.4)
+
+ Resolution:  62%
+
+– Complete:    31%
+
+– Partial:     31%
+Dose Modifications in Patients With  CSH-12
+Grade 2 Neuropathy Can Reduce
+Worsening of Neuropathy
+
+Of patients with grade 2 neuropathy
+
+   – 0/15 who had doses delayed had worsening
+
+   – 2/10 who had dose reduction had worsening
+
+   – 6/18 who had neither dose delays nor
+      reductions had worsening
+
+Both dose delays and dose reductions
+  appeared to be effective in reducing
+  progression of Grade 2 neuropathy
+                                                                                           CSH-13
+
+Management of Peripheral Neuropathy
+
+ Patients should be monitored for signs and
+   symptoms of PN
+
+ Neuropathy events
+    – Primarily sensory
+    – Appear to be associated with cumulative dosing
+    – Largely reversible
+
+ Patients experiencing new or worsening Grade 2 PN
+    – Hold dosing until resolution to Grade 1
+       or baseline
+    AND
+    – Reduce dose to 1.2 mg/kg
+                                                     CSH-14
+
+Neutropenia Experience
+
+Adverse event of neutropenia                  HL       Total
+≥ Grade 3                                  patients  patients
+                                           n = 102   N = 160
+   Median duration
+                                             20%        20%
+Grade 4                                     8 days    8 days
+   Median duration
+                                              6%        7%
+Any infections temporally associated with   4 days    6 days
+neutropenia/low neutrophils
+                                              33%      39%
+       Most < Grade 3, not serious          (7/21)    (14/36)
+Febrile neutropenia
+Discontinuation due to neutropenia             —         —
+                                               —         —
+                                                                                           CSH-15
+
+Management of Neutropenia
+
+Prolonged (≥ 1 wk) cases of Grade 4
+  neutropenia can occur
+
+CBC should be monitored with each dose
+If Grade 3 or 4 neutropenia develops,
+
+  manage according to institutional standards
+                                                                                           CSH-16
+
+Infusion-Related Reactions of Any
+Relationship Occurring in > 1 Patient
+
+                               Patients, %
+
+                               HL Total
+
+                               n = 102  N = 160
+
+Any infusion-related reaction  12 11
+     Chills
+     Nausea                    54
+     Dyspnea
+     Pruritus                  43
+     Cough
+     Dizziness                 43
+     Erythema
+     Flushing                  43
+     Pyrexia
+     Rash                      32
+     Throat tightness
+     Vomiting                  11
+
+                               21
+
+                               21
+
+                               11
+
+                               11
+
+                               21
+
+                               11
+                                CSH-17
+
+Management of Infusion-Related
+Reactions (IRR)
+
+Routine premedications not required
+In the event of IRR or anaphylaxis
+
+   – Stop infusion
+   – Institute appropriate medical management
+   – Restart infusion (at a slower rate)
+   – Premedication with subsequent infusions
+                                                                                           CSH-18
+
+Single-Event AEs
+
+ Stevens-Johnson Syndrome (SJS)
+     – HL patient receiving multiple medications including
+        naproxen
+     – Developed symptoms ~ 2 weeks after receiving his
+        second dose of brentuximab vedotin
+     – Patient discontinued treatment
+     – Event resolved in less than 1 month
+
+ Tumor Lysis Syndrome (TLS)
+     – ALCL patient with bulky disease
+     – Developed symptoms Day 1 of the Cycle 1 dose
+     – Event was considered resolved 5 days after onset
+     – Patient received a total of 8 cycles of treatment
+     – Patient had a CR and went on to allogeneic transplant
+                                                                                           CSH-19
+
+Brentuximab Vedotin Has a Manageable
+Safety Profile
+
+ Median duration of treatment: 6.2 months
+ No treatment-related deaths
+ Most common AE was peripheral neuropathy
+
+    – Primarily Grade 1 and 2 sensory
+
+    – Largely reversible
+ Grade 3/4 hematologic toxicity was limited
+ Low rate of infusion reactions observed
+
+   (Grade 1/2)
+ No evidence of cardiac, renal, or hepatic
+
+   toxicity signals
+                                                                                          CBH-1
+
+Brentuximab Vedotin
+Hodgkin Lymphoma Benefit:Risk Profile
+
+Joseph M. Connors, MD, FRCPC
+
+Clinical Director, Centre for Lymphoid Cancer
+British Columbia Cancer Agency
+University of British Columbia
+                                                                                                      CBH-2
+
+Benefit:
+Tumor Reduction
+
+94% (96 of 102)a of patients achieved tumor reduction
+
+a 4 patients not included in analysis (3, no measurable lesions per IRF; 1, no post-baseline scans).
+                                              CBH-3
+
+Benefit:
+Clinically Meaningful Results
+
+                             HL patients ALCL patients
+
+                             N = 102  N = 58
+
+Treatment response           75%      86%
+  Overall response rate      34%      57%
+  Complete remission (CR)    20.5     13.2
+  Median duration of CR, mo
+                              77%      82%
+Symptom resolution           N = 35   N = 17
+ B symptom resolution
+
+NE = Not estimable.
+                                                                                                      CBH-4
+
+Benefit:
+Population in Need: Post-transplant
+
+                100  TTR,  Median                                                               1-yr
+
+                     mo N % OS, yr mortality
+
+                80 > 12 214 28 4.6
+
+Probability, %       0 - 12 542 72 1.2                                                          > 40 %
+
+                60
+
+                40 N = 756
+
+                                                                   p < 0.001
+                20
+
+                     0
+
+                        0 5 10 15 20
+
+                                                       Time from relapse, yr
+
+TTR = Time to relapse.
+Horning et al. 10th International Conference on Malignant Lymphoma; Lugano, Switzerland; 2008.
+                                                                                CBH-5
+
+Treatment of Relapsed or Refractory
+Hodgkin Lymphoma
+
+                                All patients                Post-ASCT patients
+
+                     Evaluable                         Evaluable
+
+Agent                patients, n ORR, n (%) CR, n (%) patients, n ORR, n (%) CR, n (%)
+Vinblastinea
+Vinorelbinea         17         10 (59)       2 (12)   17         10 (59)       2 (12)
+Rituximaba
+Gemcitabinea         22         11 (50)       3 (14)
+Vinorelbine +
+Gemcitabinea         22         5 (23)        1 (5)    18         5 (23)        1 (5)
+Rituximab +
+Gemcitabinea         27         6 (22)        0        16 5 (31) 0
+Bortezomiba
+Bortezomiba          8          6 (75)        4 (50)
+Gem, Vinor, Doxb
+Panobinostatc        33         16 (48)       5 (15)   18         11 (61)
+
+Brentuximab vedotin  14         1 (7)         0        14         1 (7)                                         0
+
+                     30 0 0 28
+
+                     88         62 (70)       17 (19)  36         27 (75)       6 (17)
+
+                     129        35 (27)       5 (4)    129        35 (27)       5 (4)
+
+                     102        77 (75) 35 (34)        102        77 (75) 35 (34)
+
+a Crump M. Hema Am Soc Hematol Educ Prog. 2008:326-333; b Bartlett NL, et al. Ann Oncol. 2007;18(6):1071-1079;
+c Sureda A, et al. 52nd ASH Annual Meeting and Exposition. 2010. Abstract 169.
+                                                                                            CBH-6
+
+Benefit: Risk Ratio
+Relapsed/Refractory Hodgkin Lymphoma
+
+                                     Need
+
+ 50% relapse despite ASCT
+ 72% of relapses occur in less than 1 yr of ASCT
+
+       ~ 40% 1-yr mortality rate
+ All patients become markedly symptomatic
+ Available off-label remedies  short-term benefit in minority of patients
+ High-quality response  opportunity for potentially curative treatment
+
+             Risk                             Benefit
+
+ Peripheral neuropathy                 ORR           75%
+
+– Any grade              55%            CR            34%
+
+– Grade 3                11%            CR duration 20.5 months
+
+ Transient grade 3/4 neutropenia 20%   Potential to make eligible
+                                           for transplant
+ Infusion reactions     12%
+                   SS-1
+
+Supportive Slides
+                                    SS-2
+
+Statistical Methods—Stratification
+
+AETHERA
+
+ Best clinical response achieved after completion of
+   salvage therapy prior to ASCT
+    – CR
+    – PR
+    – SD
+
+ Prior disease status
+    – Refractory
+    – Relapsed < 12 months from the end of frontline therapy
+    – Relapsed ≥ 12 months from the end of frontline therapy
+                                                                                                   SS-3
+
+    Brentuximab Vedotin Studies Ongoing
+    and in Development
+
+Indication Study description                                               Ph 1 Ph 2 Ph 3
+
+              AETHERA—post-ASCT, high-risk HL (placebo controlled)                       X
+
+HL            Combination chemo + brentuximab vedotin in front-line HL     X
+
+              Combination chemo + brentuximab vedotin in front-line HL                   X
+
+ALCL          Combination chemo + brentuximab vedotin in front-line sALCL  X
+              Combination chemo + brentuximab vedotin in front-line sALCL
+                                                                                         X
+
+              Re-treatment                                                    X
+
+CD30+         Cardiac safety (primary data complete)                       X
+malignancies  Drug-drug interaction/Special populations                    X
+              CD30+ NHL
+                                                                                      X
+
+              CD30+ non-lymphomatous malignancies                             X
+
+CTCL          Single agent vs physicians choice in CD30+ CTCL                            X
+
+              Open          In Development
+Complete Remissions by Additional                         SS-4
+Subgroups—March 2011
+                                                       CR / N
+Hodgkin Lymphoma                                       35 / 102
+
+Subgroups                           Overall CRR = 34%   1 /1
+Overall                                                33 / 98
+Age                       12 - 17
+                          18 - 64                       1 /3
+Sex                       ≥ 65                         14 / 48
+                          Male                         21 / 54
+Baseline weight           Female                       29 / 91
+                          ≤ 100 kg
+Relapse                   > 100 kg                      6 / 11
+Refractory                                             21 / 59
+Bone marrow involvement   Present                      14 / 43
+                          Absent
+Baseline LDH              Normal                        0 /8
+                          High                         35 / 94
+Treatments post-ASCT      0                            25 / 65
+                          ≥1                           10 / 37
+Treatments prior to ASCT  ≤2                           17 / 45
+                          >2                           18 / 57
+Prior radiotherapy        Yes                          22 / 57
+                          No                           13 / 45
+                                                       22 / 67
+                                                       13 / 35
+PFSa: Brentuximab Vedotin vs Last                                                            SS-5
+
+Prior Post-ASCT Therapy—March 2011
+
+Hodgkin Lymphoma
+
+                                                                                              Median
+                                                                                             PFS , mo
+
+                  PFS per investigator                                                       7.8
+
+                  PFS most recent prior therapy 4.1
+
+                  HR = 0.41 (p < 0.001)
+
+a PFS as assessed by investigator in the subset of
+patients (n = 57) who received systemic therapy post-ASCT and prior to brentuximab vedotin.
+Combination of Brentuximab Vedotin SS-6
+With ABVD Provides Better Efficacy Than
+Either Agent Alone
+
+Tumor volume, mm3  1200                                                  Untreated
+                                                                         Brentuximab vedotin
+                   1000                                                  (1 mg/kg, q4dx3) ip (4/9 DRs)
+                                                                         ABVD (8/8 CRs / 0/8 DRs)
+                    800                                                  Brentuximab vedotin + ABVD
+                                                                         (9/9/DRs)
+                    600
+                                                                                   L540cy-70B
+                    400
+
+                    200
+
+                        0
+                           0 10 20 30 40 50 60 70 80 90
+
+                                                    Days
+
+ABVD = Doxorubicin (1 mg/kg, q4dx3) iv; bleomycin (7.5 u/kg, q4dx3) ip;
+vinblastine (0.015 mg/kg q4dx3) ip; dacarbazine (20 mg/kg, q3dx4) ip.
+                                                                                                    SS-7
+
+Best Clinical Response by Immunogenicity
+Status in Baseline Negative Patients
+
+Phase 2 Population
+
+                                                                        HL patients, n (%)
+                                                                                n = 96
+
+                                                                        Transient  Persistent
+                                                                                    positive
+                                     Negative positive                                n=7
+
+                                     n = 64                             n = 24
+
+Objective response rate (CR + PR)    49 (77)                            16 (67)             6 (86)
+Disease control rate (CR + PR + SD)
+                                     63 (98)                            22 (92)    7 (100)
+
+                                                                        ALCL patientsa, n (%)
+                                                                                  N = 54
+
+                                                                        Transient  Persistent
+                                                                                    positive
+                                     Negative positive                                n=3
+
+                                     n = 32                             n = 18
+
+Objective response rate (CR + PR)    28 (88)                            15 (83)    3 (100)
+Disease control rate (CR + PR + SD)
+                                     29 (91)                            16 (89)    3 (100)
+
+a Independent review facility assessment per Revised Response Criteria
+for Malignant Lymphoma.
+
\ No newline at end of file
diff --git a/src/main/webapp/resources/docs/virtuallearning/D_Med_3.pdf b/src/main/webapp/resources/docs/virtuallearning/D_Med_3.pdf
new file mode 100644
index 0000000..2a183d5
--- /dev/null
+++ b/src/main/webapp/resources/docs/virtuallearning/D_Med_3.pdf
@@ -0,0 +1,1501 @@
+                                    CIH-1
+
+ADCETRIS™
+Brentuximab Vedotin
+
+CD30-Directed Therapy for
+Hodgkin Lymphoma
+
+Oncologic Drugs Advisory Committee
+
+July 14, 2011
+                                                                                           CIH-2
+
+Brentuximab Vedotin
+Hodgkin Lymphoma
+Introduction
+
+Elaine Waller, PharmD
+
+Senior Vice President of Regulatory Affairs
+Seattle Genetics
+                                                                                              CIH-3
+
+Brentuximab Vedotin Targets CD30 Antigen
+
+Transmembrane glycoprotein receptor,
+  member of TNF receptor superfamily
+
+Leads to transduction of biologic signals,
+  including cell proliferation
+
+Highly expressed on HL and ALCL cells
+Restricted distribution on normal cells:
+
+   – Expressed on activated lymphocytes
+      (B cell, T cell, NK cell)
+
+   – Weakly expressed on activated monocytes
+                                                                         CIH-4
+
+CD30+ Lymphomas
+
+                                 Lymphoma  Non-Hodgkin lymphoma
+Hodgkin lymphoma
+
+B-cell neoplasms                           T-cell & NK-cell neoplasms
+
+                  Peripheral T-cell lymphoma &                   Cutaneous TCL
+                  Natural killer T-cell lymphoma
+
+                                           PTCL not otherwise specified
+
+                                           Systemic anaplastic large cell lymphoma
+
+                                           Angio-immunoblastic TCL
+
+                                           Other PTCLs
+Comparison of Unconjugated CD30 mAb CIH-5
+With Brentuximab Vedotin
+Hodgkin Lymphoma
+
+Dose             CD30 mAb                                 Brentuximab vedotin
+               (unconjugated                              (conjugated cAC10)
+Patients, n
+Objective           cAC10)                                        1.8 mg/kg
+response rate  6 or 12 mg/kg                                  every 3 weeks
+Complete
+remissions          weekly                                            102
+                       38                                             75%
+                        —
+                                                                      34%
+                       —
+
+Forero-Torres A, et al. Br J Haematol. 2009;146:171-179.
+                                                                                                             CIH-6
+
+Brentuximab Vedotin Structure
+
+Antibody                             Linker                                      Drug
+
+cAC10 anti-CD30 Attachment                 Protease-                             MMAE
+                                                                           cytotoxic agent
+antibody  group                      cleavage site
+
+                                  O  O          H  O              O     H  O               N            HO
+          S                             N       N     N        ON       N     N  OCH3O                    N
+                                        H    O        H              O                                    H
+                              N
+                        O                                                                     OCH3O
+
+                                                        NH
+                                                   O
+
+                                                          NH2
+                                                                                              CIH-7
+
+Brentuximab Vedotin Is More Active Than
+MMAE Alone
+
+Tumor volume, mm3  1200
+
+                   1000
+
+                   800
+
+                   600
+
+                   400
+
+                   200
+
+                   0
+                      0 20 40 60 80 100 120
+
+                                                  Days
+
+Untreated (0/5 DR)        Control ADC 2 mg/kg (0/5 DR)
+MMAE 0.25 mg/kg (0/5 DR)  Brentuximab vedotin 2 mg/kg (4/5 DR)
+
+DR = Durable response.
+HL L428 subcutaneous xenograft model in NSG mice (n = 5 group), mean ± SD, q4dx3.
+                                                                                                         CIH-8
+
+Brentuximab Vedotin
+Mechanism of Action
+
+                                                        1. ADC binds to CD30
+
+2. ADC-CD30 complex is  CD30
+internalized and
+trafficks to lysosome
+
+3. MMAE is
+released
+
+                                                                              6. Apoptosis (cell death)
+
+4. MMAE binds           5. G2/M cell
+tubulin and             cycle arrest
+prevents microtubule
+assembly
+                         CIH-9
+
+Proposed Indication and
+Dosage Regimen
+
+Brentuximab vedotin is a CD30-directed
+  antibody-drug conjugate indicated for the
+  treatment of patients with relapsed or
+  refractory Hodgkin lymphoma
+
+Brentuximab vedotin 1.8 mg/kg administered
+  as an IV infusion over 30 minutes every
+  3 weeks
+
+Treat until disease progression or
+  unacceptable toxicity
+                                          CIH-10
+
+Brentuximab Vedotin in Patients With
+Hodgkin Lymphoma
+
+ Efficacy
+   – Clinically relevant objective
+      response rates
+   – Durable complete remissions
+   – Resolution of disease-related signs
+      and symptoms
+
+ Safety
+   – Most common AEs were grade 1 and 2
+   – Peripheral neuropathy is manageable
+                                                                                         CIH-11
+
+Clinical Trials Submitted in BLA
+
+   IND             EOP1 Phase 2 Clin Pharm        Clinical  BLA
+submitted        meeting SPA meeting              pre-BLA   submission
+                                                  meeting   Feb
+   Jun                Jul Jan Mar
+                                                       Nov
+
+2006       2007  2008          2009         2010            2011
+
+                 Phase 1 q3wk
+
+                               Phase 1 q1wk
+                                              Pivotal HL study
+
+                                             Pivotal ALCL study
+                                                                 QTc
+
+                                                           Excretion
+                                                              DDI
+                                                                    Special populations
+                                                                                            CIH-12
+
+Special Protocol Assessment
+
+ Agreements made with the FDA
+    – Primary endpoint
+
+          • ORR per independent review facility (IRF)
+          • 2007 Revised Response Criteria for Malignant Lymphoma
+
+    – ORR of 30% considered a meaningful response
+    – Supporting evidence
+
+          • Duration of response
+          • Complete remission
+          • B symptom resolution
+          • Investigator assessment vs IRF concordance
+
+ SPA remains in effect
+                                                                                            CIH-13
+
+AETHERA: Phase 3 HL Post-ASCT
+
+ Randomized, double-blind, placebo-controlled, multicenter,
+    phase 3 clinical trial
+
+ Patients randomized 1:1 to receive brentuximab vedotin or
+    placebo every three weeks
+
+ Efficacy endpoints
+     – Primary: Progression-free survival per IRF
+     – Key Secondary: Overall survival
+
+ Population (N = 322) includes at least one of the following
+     – Refractory to front-line therapy
+     – Relapsed within 12 months
+     – Extranodal disease
+
+ Stratified by response to frontline and salvage treatments
+                                 CIH-14
+
+Ongoing Clinical Development in
+Hodgkin Lymphoma
+
+ AETHERA - Phase 3 trial in patients at high risk
+   of residual HL following autologous SCT
+
+ Phase 1 trial in front-line HL
+
+ Expanded access program in relapsed or
+   refractory HL and systemic ALCL
+                                                        CIH-15
+
+Today’s Agenda
+
+Introduction          Elaine Waller, PharmD
+                      Seattle Genetics
+
+CD30-Directed Therapy for Joseph M. Connors, MD, FRCPC
+
+Hodgkin Lymphoma      British Columbia Cancer Agency
+
+Brentuximab Vedotin   Eric Sievers, MD
+Hodgkin Lymphoma      Seattle Genetics
+Efficacy Profile
+
+Brentuximab Vedotin   Tom Reynolds, MD, PhD
+Safety Profile        Seattle Genetics
+
+Hodgkin Lymphoma      Joseph M. Connors, MD, FRCPC
+Benefit:Risk Profile  British Columbia Cancer Agency
+                                                              CIH-16
+
+Consultants
+
+ David R. Cornblath, MD          J. Michael O’Neal, MD
+    Professor, Neurology             Chief Medical Officer
+    Johns Hopkins University         CoreLab Partners
+
+ L. Jeffrey Medeiros, MD         Barbara Pro, MD
+    Professor, Chair, Dept of        Associate Professor
+    Hematopathology                  Fox Chase Cancer Center
+    MD Anderson Cancer Center
+
+ Owen O’Connor, MD
+    Deputy Director of Clinical
+    Research and
+    Cancer Treatment
+    New York University Cancer
+    Institute
+                                                                                          CDH-1
+
+Brentuximab Vedotin
+CD30 Directed Therapy for
+Hodgkin Lymphoma
+
+Joseph M. Connors, MD, FRCPC
+
+Clinical Director, Centre for Lymphoid Cancer
+British Columbia Cancer Agency
+University of British Columbia
+                                                                                   CDH-2
+
+Disclosures
+
+                          Not-for-profit Sources               For-profit Sources
+
+Institutional       Canadian Cancer Society Research     Amgen              Bayer Healthcare
+research support    Institute                            Cephalon           Lilly
+including clinical  NCI of Canada Clinical Trials Group  Genentech          Merck
+trials              Terry Fox Foundation                 Hoffmann-La Roche  Roche Canada
+                    SWOG                                 Johnson & Johnson  Seattle Genetics
+Advisory
+Board/Committee     ASH                                  None
+                    ASCO
+Employee            Lymphoma Foundation Canada
+Speakers’ Bureau    Lymphoma Research Foundation (US)
+Honoraria           NCIC Canada
+Board member
+Paid consultant     British Columbia Cancer Agency       None
+Stockholder
+                    ASH                                  None
+
+                    ASH, ASCO                            None
+
+                    None                                 None
+
+                    None                                 None
+
+                    None                                 None
+
+                                                                            July 2011
+                                                                                            CDH-3
+
+CD30: Optimal Target for Antibody-Drug
+Conjugate Therapy
+
+Highly restricted normal cell surface
+  expression
+
+Defining marker for Hodgkin lymphoma—
+  malignant Hodgkin Reed-Sternberg cells
+
+Standard immunohistochemical test
+
+   – Widely available
+
+   – Reliable and reproducible
+                                                                                 CDH-4
+
+Hodgkin Reed-Sternberg Cells
+Strongly Express CD30
+
+                                                                       CD30+
+                                                                       HRS cell
+
+Cytokine receptor CD30 selectively
+         expressed in HRS cells
+                                                                                                 CDH-5
+
+  Hodgkin Lymphoma
+
+    2010 estimatesa
+       – 8490 new cases of HL were diagnosed
+       – 1320 patients would die from their disease
+
+    Median age at diagnosis is 38 yearsb
+       – 90% of patients < 60 years
+
+    Clinical presentation
+       – Painless, enlarged lymph nodes commonly in
+          the neck and thorax
+       – 15% of patients with B symptoms (fever,
+          night sweats, weight loss > 10%)
+
+a Jemal A, et al. CA Cancer J. 2010;60(5):277-300; b National Cancer Institute. 2010. Surveillance, Epidemiology, and
+End Results (SEER) Program SEER*Stat Database: Incidence. http://seer.cancer.gov/canques/incidence.html.
+Progression-Free Survival by                                                            CDH-6
+Decade of Diagnosis
+
+Hodgkin Lymphoma
+
+         1.0                                      N = 3216
+         0.8
+         0.6                 Cumulative survival  2000s  1990s, bone marrow transplantation
+         0.4
+         0.2                                                          1980s, ABVD
+
+            0                                                                        1970s, wide field
+               0                                                                     radiation and MOPP-
+                                                                                     type chemotherapy
+Data courtesy of Dr. Connors.
+                                                                                        1960s
+
+                                                  10 20 30                          40
+                                                  Progression-free survival, years
+                                                                                            CDH-7
+
+Treatment Algorithm for Advanced-Stage
+Hodgkin Lymphoma
+
+First-line   Multi-agent     ABVD or Stanford V or BEACOPP                           Current
+treatment   chemotherapy                                                           unmet need
+
+                  70% cured  ± RT                             30% Progressive
+                                                              disease or relapse
+Second-line                  Combination chemotherapy                              30%
+treatment                        (eg, DHAP, ICE, GVD)            30% < CR/PR
+(including ASCT)
+                                       70% CR/PR
+
+                                                              No standard of care
+
+                                 High-dose therapy with
+                             autologous stem cell transplant
+
+Post-ASCT         50% cured                                   50% Progressive      50%
+                                                              disease or relapse
+
+ASCT = Autologous stem cell transplant; CR = Complete remission; PR = Partial remission; RT = Radiation therapy.
+                                                                                                CDH-8
+
+Poor Survival in HL Patients Who
+Relapse After a Stem Cell Transplant
+
+Overall survival in patients who relapse post-ASCT (N = 756)
+   100
+
+                80
+
+Probability, %  60
+
+                                 Median = 2.4 yr
+
+                40
+
+                20
+
+                     0
+                        0 5 10 15 20
+
+                                                       Time from relapse, yr
+
+Horning et al. 10th International Conference on Malignant Lymphoma; Lugano, Switzerland; 2008.
+72% of Relapses After ASCT Occur in CDH-9
+the First 12 Months and Have a Very
+Poor Prognosis
+
+                100 1-yr mortality 40%
+
+                    TTR, mo N % Median OS, yr
+
+                80  > 12 214 28                                            4.6
+
+Probability, %      0 - 12 542 72                                          1.2
+
+                60
+
+                40 N = 756
+                                                                p < 0.001
+
+                20
+
+                     0
+
+                        0 5 10 15 20
+
+                                                       Time from relapse, yr
+
+TTR = Time to relapse.
+Horning et al. 10th International Conference on Malignant Lymphoma; Lugano, Switzerland; 2008.
+                                                                                           CDH-10
+
+Treatment Options After Failure of ASCT
+
+No reliably curative options
+   – Experimental allogeneic SCT
+       • Applicable to small minority
+       • Associated with marked toxicity
+   – Curative wide-field radiation applicable
+      to < 5%
+
+No approved treatment
+Pronounced unmet need
+                                                                              CDH-11
+
+Treatment of Relapsed or Refractory
+Hodgkin Lymphoma
+
+                               All patients               Post-ASCT patients
+
+Agent             Evaluable                                        Evaluable
+Vinblastinea      patients, n  ORR, n (%) CR, n (%) patients, n ORR, n (%) CR, n (%)
+Vinorelbinea
+Rituximaba        17           10 (59)       2 (12)  17   10 (59)             2 (12)
+Gemcitabinea
+Vinorelbine +     22           11 (50)       3 (14)
+Gemcitabinea
+Rituximab +       22           5 (23)        1 (5)   18   5 (23)              1 (5)
+Gemcitabinea
+Bortezomiba       27           6 (22)        0       16 5 (31) 0
+Bortezomiba
+Bortezomiba       8            6 (75)        4 (50)
+
+Gem, Vinor, Doxb  33           16 (48)       5 (15)  18   11 (61)
+Panobinostatc
+                  14           1 (7)         0       14   1 (7)                                                 0
+
+                  30 0 0 28
+
+                  12 0 0
+
+                  88           62 (70) 17 (19)       36   27 (75) 6 (17)
+
+                  129          35 (27)       5 (4)   129  35 (27)             5 (4)
+
+a Crump M. Hema Am Soc Hematol Educ Prog. 2008:326-333; b Bartlett NL, et al. Ann Oncol. 2007;18(6):1071-1079;
+c Sureda A, et al. 52nd ASH Annual Meeting and Exposition. 2010. Abstract 169.
+                                                                                           CDH-12
+
+Key Concepts for Patients With Relapsed
+or Refractory Hodgkin Lymphoma
+
+Background                                            Hodgkin
+• Malignant cells express CD30                       lymphoma
+Disease impact
+• Not cured with current standard treatments          ~ 100 %
+• Median OS
+                                                        ~ 25%
+  – After failure of autologous transplant
+  – Post-ASCT failure in < 1 year                       29 mo
+• Typical response to available treatment = partial     14 mo
+• Typical duration of response                       20% - 60%
+                                                      3 - 12 mo
+                                                                                          CEH-1
+
+Brentuximab Vedotin Treatment of
+Patients With Hodgkin Lymphoma
+
+Eric Sievers, MD
+
+Vice President of Clinical Affairs
+Seattle Genetics
+                                                                                    CEH-2
+
+Brentuximab Vedotin Clinical
+Development Program
+
+2006  2007  2008          2009  2010  2011
+
+            Phase 1 q3wk
+
+                          Phase 1 q1wk
+                                         Pivotal HL study
+
+                                        Pivotal ALCL study
+                                                            QTc
+
+                                                      Excretion
+                                                         DDI
+                                                               Special populations
+                                                                                                 CEH-3
+
+  Phase 1 First-in-Human Study
+
+      Phase 1 dose-escalation study of brentuximab vedotin in patients with
+         relapsed or refractory CD30+ hematological malignancies
+
+      N = 45 enrolled at 4 US sites
+           – Median age of 36 years
+           – HL (n = 42), sALCL (n = 2), and angioimmunoblastic T-cell
+               lymphoma (n = 1)
+           – Median 3 prior regimens; prior ASCT in 73%
+
+      Brentuximab vedotin was given intravenously every 3 weeks in
+         escalating doses ranging from 0.1 to 3.6 mg/kg in successive cohorts
+
+      1.8 mg/kg every 3 weeks
+           – Defined as MTD; also reasonably well-tolerated over months of
+               continued therapy
+           – Obtained durable complete remissions
+           – Employed in the subsequent, paired registrational trials
+
+a Younes A, et al. N Engl J Med. 2010;363(19):1812-1821.
+                                                    CEH-4
+
+Results
+
+Phase 1 Program—Hodgkin Lymphoma
+
+Overall response rate                 Q 3 week        Q 1 week
+    Complete remission rate               trial           trial
+
+Median, months (min - max)              n = 42          n = 38
+    Duration of overall response          36%             53%
+                                          21%             26%
+    Duration of complete remission
+                                           NE              4.8
+                                    (0.6 - 19.4+)   (0.5+ - 17.3+)
+
+                                           NE              5.1
+                                    (1.4+ - 19.4+)  (0.5+ - 17.3+)
+                                                                                    CEH-5
+
+Brentuximab Vedotin Clinical
+Development Program
+
+2006  2007  2008          2009  2010  2011
+
+            Phase 1 q3wk
+
+                          Phase 1 q1wk
+                                         Pivotal HL study
+
+                                        Pivotal ALCL study
+                                                            QTc
+
+                                                      Excretion
+                                                         DDI
+                                                               Special populations
+                                                                                                          CEH-6
+
+Phase 2 Pivotal, Multicenter,
+Open-Label Trial Endpoints
+
+ Primary: Overall objective response rate (CR + PR)
+
+– Independent review facility
+
+– Revised response criteria for malignant
+  lymphomaa
+
+ Secondary
+
+– Efficacy   – Safety
+
+• Duration of response • Adverse events
+
+• CR rate                      • Laboratory
+
+• PFS                          abnormalities
+
+• OS
+
+• B symptom resolution
+
+CR = Complete remission; PR = Partial remission; PFS = Progression-free survival; OS = Overall survival.
+a Cheson BD, et al. J Clin Oncol. 2007;25(5):579-586.
+                                                                                                 CEH-7
+
+2007 Revised Response Criteria for
+Malignant Lymphoma
+
+Response  Definition               Nodal lesions
+CR
+PR        Disappearance of all     Residual mass of any size
+          evidence of disease      permitted if PET-negative
+SD
+          Regression of            ≥ 50% decrease in SPD of index
+PD
+          measurable disease and lesions; 1 or more PET-positive at
+
+          no new sites             previously involved site
+
+          Failure to attain CR/PR  PET-positive at previously
+          or PD                    involved site and no new sites
+                                   of disease
+
+          Any new lesion or        Progression of existing non-index
+          increase by ≥ 50% of     lesions or ≥ 50% increase in SPD
+          previously involved      of index lesions or new lesion
+
+          sites from nadir         > 1.5 cm in any axis
+
+CR = Complete remission; PR = Partial remission; SD = Stable disease; PD = Progressive disease;
+SPD = Sum of the products of the diameters.
+Cheson BD, et al. J Clin Oncol. 2007;25(5):579-586.
+                                                                                             CEH-8
+
+Pivotal, Multicenter, Open-Label Trials of
+Brentuximab Vedotin
+
+     Brentuximab vedotin 1.8 mg/kg IV over 30 minutes every 3 weeks
+
+S  E Follow-up
+C
+R  N every
+E
+E  R 12 weeks
+N
+I  O
+N
+G  L
+
+   L 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
+   M
+   E  Cycle
+
+   N
+
+   T
+
+   CT scan between Days 15 and 21 of cycle
+   PET scan (no additional scans past Cycle 7 unless clinically indicated)
+                                           CEH-9
+
+Key Eligibility Criteria
+
+Hodgkin Lymphoma
+
+Relapsed or refractory, progressive HL
+CD30 expression confirmed centrally
+FDG-avid, CT-measurable disease ≥ 1.5 cm
+Prior ASCT was required
+Age ≥ 12 years
+ECOG performance status score 0 to 1
+                              CEH-10
+
+Statistical Considerations
+
+Hodgkin Lymphoma
+
+Trial and analyses conducted under Special
+  Protocol Assessment
+
+Primary statistical hypothesis: ORR 95% CI
+  lower bound > 20%
+
+   – Study size of 100 patients was chosen to
+      allow evaluation of primary hypothesis
+
+   – Observation of an ORR of 29% or greater
+      would exclude a lower bound of 20%
+
+ORR = Overall response rate.
+                             CEH-11
+
+Study Conduct and Oversight
+
+Hodgkin Lymphoma
+
+Study steering committee guided design,
+  conduct, and data interpretation
+
+Independent data monitoring committee
+  actively evaluated for safety signals
+
+Independent response assessments
+
+   – Prospectively rendered by central
+      radiology blinded to clinical data
+
+   – Overall assessment additionally integrated
+      clinical data
+Demographics and                                            CEH-12
+Baseline Characteristics
+                                                   N = 102
+ Hodgkin Lymphoma                               31 (15 - 77)
+                                                48 M / 54 F
+Median age, yr (range)
+Gender, n                                              41
+ECOG performance status score, %                       59
+                                                       71
+    0                                                  42
+    1                                           3.5 (1 - 13)
+Refractory to front-line therapy, %                    66
+Refractory to most recent treatment, %               100
+Median prior chemotherapy regimens, n (range)          71
+Prior radiation, %                              6.7 (0 - 131)
+Prior ASCT, %
+Relapsed ≤ 1 yr post-ASCT, %
+Median time from ASCT to first post-transplant
+relapse, months (range)
+  Response Results                                                                            CEH-13
+
+   Hodgkin Lymphoma                                                      N = 102
+                                                                       75 (65, 83)
+       Overall response rate, % (95% CI)                               34 (24, 44)
+           Complete remission, % (95% CI)
+           Partial remission, %                                              40
+
+       Median, months (95% CI)                                       6.7 (3.6, 14.8)
+           Duration of overall response                              20.5 (10.8, NE)
+           Duration of complete remission
+           Progression-free survival                                  5.6 (5.0, 9.0)
+           Overall survivala                                         22.4 (21.7, NE)
+
+       B-symptom resolution, % (n/N)                                   77% (27/35)
+
+NE = Not estimable.
+a 18-month overall survival estimated to be 80% (95% CI: 73%, 88%).
+                                                                          CEH-14
+
+Maximum Tumor Reduction
+
+Hodgkin Lymphoma
+
+94% (96 of 102)a of patients achieved tumor reduction
+
+a 4 patients not included in analysis (3, no measurable lesions per IRF;
+1, no post-baseline scans).
+                                                                                           CEH-15
+
+PFS by Best Clinical Response per IRF
+
+Hodgkin Lymphoma
+
+N Median, mo
+
+CR 35 21.7
+
+PR 41  5.1
+
+SD 22  3.5
+
+PD 3   1.2
+                                                                                           CEH-16
+
+CR Rate Was Similar in All Patient Subsets
+
+Hodgkin Lymphoma
+
+Subgroups                                      Overall CR rate = 34%  CR / N
+Overall                                                               35 / 102
+Primary refractory    Yes                                             26 / 72
+                      No
+Time to relapse       ≤ 1 yr                                            9 / 30
+post-ASCT             > 1 yr                                          18 / 72
+Baseline B symptoms   Yes                                             17 / 30
+present               No                                              10 / 35
+Baseline ECOG         0                                               25 / 67
+                      1                                               19 / 42
+Baseline SPD per IRF  ≤ 5 cm2                                         16 / 60
+                      > 5 and ≤ 10 cm2
+                      > 10 cm2                                          3 / 11
+                                                                        9 / 11
+                                                                      22 / 77
+Overall Survival                                            CEH-17
+                  89% estimated 12-month OS
+Hodgkin Lymphoma
+                                                                                           CEH-18
+
+Consistent Response Rates
+
+Pivotal Studies in Two CD30+ Lymphomas
+
+Treatment response                    HL patients  ALCL patients
+  Overall response rate, % (95% CI)     N = 102         N = 58
+
+ Complete remission, % (95% CI)             75             86
+                                         (65, 83)       (75, 94)
+  Median duration of response for CR
+  patients, mo (95% CI)                     34             57
+                                         (25, 44)       (43, 70)
+
+                                           20.5           13.2
+                                       (10.8, NE)     (10.8, NE)
+
+NE = Not estimable.
+Change in tumor size from baseline %                                                                                           CEH-19
+
+                                    Consistent Tumor Reduction
+
+                                    Pivotal Studies in Two CD30+ Lymphomas
+
+                                                                                                                                                       HL
+
+                                                                                                                                     Systemic ALCL
+                                                                                           CEH-20
+
+Durable Complete Remission Represents
+Clinical Benefit in CD30+ Lymphoma Patients
+
+                                      CD30+ lymphomas
+
+           Hodgkin                       Systemic ALCL
+          lymphoma
+
+Q3 week    Weekly        Pivotal study         Pivotal study
+  N = 42    N = 38           N = 102                N = 58
+          ORR 53%           ORR 75%
+ORR 36%    CR 26%            CR 34%,             ORR 86%
+ CR 21%                                           CR 57%,
+                    median CR = 20.5 mo  median CR = 13.2 mo
+                       CSH-1
+
+Brentuximab Vedotin
+Safety Profile
+
+Tom Reynolds, MD, PhD
+
+Chief Medical Officer
+Seattle Genetics
+                                             CSH-2
+
+Safety Profile of Brentuximab Vedotin
+
+        Phase 2
+Safety and efficacy
+
+HL pivotal  ALCL pivotal
+ (n = 102)     (n = 58)
+
+Total Phase 2: N = 160      Total number of
+                           patients exposed
+          Phase 1
+           Safety             in completed
+                                  studies
+Q 3 week    Q 1 week
+ (n = 45)    (n = 44)             N = 357
+
+Clinical pharmacology
+
+  QTc       DDI/excretion
+(n = 52)        (n = 56)
+                                                      CSH-3
+
+Brentuximab Vedotin Exposure
+
+Median treatment                     HL patients      Total patients
+Cycles, n (range)                       n = 102           N = 160
+Duration, mo (range)
+Relative dose intensity, % (range)    9.0 (1 - 16)      7.0 (1 - 16)
+                                    6.2 (0.7 - 12.9)  5.5 (0.7 - 12.9)
+                                    96.0 (69 - 107)   97.3 (47 - 115)
+                                                     CSH-4
+
+Dose Modifications
+
+ Dose modifications were prospectively defined in
+   study protocols
+
+ Patients could have their dose delayed up to
+   3 weeks or reduced to 1.2 mg/kg for AEs
+
+Per-protocol and unplanned                               Patients, %
+dose modifications                                      HL Total
+Dose reduction                                       n = 102 N = 160
+Dose delaya                                             11 10
+Dose adjustment due to an AE                            47 41
+                                                        12 8
+
+a Only 8% of total doses were delayed due to an AE.
+                                          CSH-5
+
+Patient Disposition
+
+                     HL patients, N  102
+Enrolled, n                          102
+Received ≥ 1 dose, n
+
+Reason for treatment discontinuation, %
+
+Completed treatment                  18
+
+Progressive disease                  44
+
+Adverse event                        20
+
+Investigator decision                12
+
+Patient decision, non-AE             7
+                                                                                             CSH-6
+
+Adverse Events of Any Relationship
+Occurring in ≥ 20% of Phase 2 Patients
+
+                                        Patients, %
+
+Preferred term                             HL     Total
+Peripheral sensory neuropathy           n = 102  N = 160
+Fatigue
+Nausea                                  47 44
+Diarrhea
+Pyrexia                                 46 42
+Upper respiratory tract infection
+Neutropenia                             42 41
+Vomiting
+                                        36 34
+
+                                        29 31
+
+                                        37 28
+
+                                        22 21
+
+                                        22 20
+
+a Only 8% of total doses were delayed.
+                                                                                             CSH-7
+
+Adverse Events Grade 3-4 Occurring in
+≥ 2% of Phase 2 Patients
+
+                    HL patients, %         Total patients, %
+                         n = 102                 N = 160
+
+Preferred term       Any                    Any
+Peripheral sensory  grade Grade 3 Grade 4  grade Grade 3 Grade 4
+neuropathy
+Fatigue             47 8            —      44 9  —
+Diarrhea
+Pyrexia             46 2            — 42   2     1
+Neutropenia         36 1                         —
+Thrombocytopenia    29 2            — 34   2     —
+Peripheral motor    22 14                        7
+neuropathy          86              — 31   2     3
+                    12 1                         —
+                                    6 21 13
+
+                                    2 10 7
+
+                                    —9 2
+
+Total patients with any ≥ Grade 3 event = 55%
+Summary of Deaths                                           CSH-8
+
+All deaths                           Patients, n
+   Related to disease               HL Total
+   Not related to disease        n = 102 N = 160
+   Disease relationship unknown     13 25
+                                    10 18
+Deaths < 30 days of last dose
+                                      25
+                                      12
+                                     —6
+                           CSH-9
+
+Special Safety Topics and
+Management of Toxicity
+                                                                           CSH-10
+
+Peripheral Neuropathy AEs
+
+                                                        HL patients, %  Total patients, %
+                                                             n = 102          N = 160
+
+                                                        Any grade Grade 3 Any grade Grade 3
+
+Any PN SMQ AEa                                          55 11 53 11
+
+Peripheral sensory neuropathy                           47  8 44           9
+
+Peripheral motor neuropathy                             12  1           9  2
+
+Paresthesia                                             4—4—
+
+Demyelinating polyneuropathy                            2   2           1  1
+
+Hypoesthesia                                            2—1—
+
+Muscular weakness                                       2111
+
+Neuralgia                                               —— 1 —
+
+SMQ = Standard MedDRA query.
+a Events of any relationship occurring in > 1 patient.
+                                                                                           CSH-11
+
+Characterization of Treatment-Emergent
+Peripheral Neuropathy
+
+Total Phase 2 Population
+
+                                          Weeks to onset
+0 12 24 36 48
+
+  Any PN       Grade 2 PN Grade 3 PN
+  (n = 84)
+   12 wk       (n = 41) (n = 18)
+(0.1 - 41.3)
+               24 wk  33 wk
+
+               (0.1 - 51.9) (6.0 - 57.1)
+
+ Median time to complete or partial resolution: 6.6 wk (0.3, 54.4)
+
+ Resolution:  62%
+
+– Complete:    31%
+
+– Partial:     31%
+Dose Modifications in Patients With  CSH-12
+Grade 2 Neuropathy Can Reduce
+Worsening of Neuropathy
+
+Of patients with grade 2 neuropathy
+
+   – 0/15 who had doses delayed had worsening
+
+   – 2/10 who had dose reduction had worsening
+
+   – 6/18 who had neither dose delays nor
+      reductions had worsening
+
+Both dose delays and dose reductions
+  appeared to be effective in reducing
+  progression of Grade 2 neuropathy
+                                                                                           CSH-13
+
+Management of Peripheral Neuropathy
+
+ Patients should be monitored for signs and
+   symptoms of PN
+
+ Neuropathy events
+    – Primarily sensory
+    – Appear to be associated with cumulative dosing
+    – Largely reversible
+
+ Patients experiencing new or worsening Grade 2 PN
+    – Hold dosing until resolution to Grade 1
+       or baseline
+    AND
+    – Reduce dose to 1.2 mg/kg
+                                                     CSH-14
+
+Neutropenia Experience
+
+Adverse event of neutropenia                  HL       Total
+≥ Grade 3                                  patients  patients
+                                           n = 102   N = 160
+   Median duration
+                                             20%        20%
+Grade 4                                     8 days    8 days
+   Median duration
+                                              6%        7%
+Any infections temporally associated with   4 days    6 days
+neutropenia/low neutrophils
+                                              33%      39%
+       Most < Grade 3, not serious          (7/21)    (14/36)
+Febrile neutropenia
+Discontinuation due to neutropenia             —         —
+                                               —         —
+                                                                                           CSH-15
+
+Management of Neutropenia
+
+Prolonged (≥ 1 wk) cases of Grade 4
+  neutropenia can occur
+
+CBC should be monitored with each dose
+If Grade 3 or 4 neutropenia develops,
+
+  manage according to institutional standards
+                                                                                           CSH-16
+
+Infusion-Related Reactions of Any
+Relationship Occurring in > 1 Patient
+
+                               Patients, %
+
+                               HL Total
+
+                               n = 102  N = 160
+
+Any infusion-related reaction  12 11
+     Chills
+     Nausea                    54
+     Dyspnea
+     Pruritus                  43
+     Cough
+     Dizziness                 43
+     Erythema
+     Flushing                  43
+     Pyrexia
+     Rash                      32
+     Throat tightness
+     Vomiting                  11
+
+                               21
+
+                               21
+
+                               11
+
+                               11
+
+                               21
+
+                               11
+                                CSH-17
+
+Management of Infusion-Related
+Reactions (IRR)
+
+Routine premedications not required
+In the event of IRR or anaphylaxis
+
+   – Stop infusion
+   – Institute appropriate medical management
+   – Restart infusion (at a slower rate)
+   – Premedication with subsequent infusions
+                                                                                           CSH-18
+
+Single-Event AEs
+
+ Stevens-Johnson Syndrome (SJS)
+     – HL patient receiving multiple medications including
+        naproxen
+     – Developed symptoms ~ 2 weeks after receiving his
+        second dose of brentuximab vedotin
+     – Patient discontinued treatment
+     – Event resolved in less than 1 month
+
+ Tumor Lysis Syndrome (TLS)
+     – ALCL patient with bulky disease
+     – Developed symptoms Day 1 of the Cycle 1 dose
+     – Event was considered resolved 5 days after onset
+     – Patient received a total of 8 cycles of treatment
+     – Patient had a CR and went on to allogeneic transplant
+                                                                                           CSH-19
+
+Brentuximab Vedotin Has a Manageable
+Safety Profile
+
+ Median duration of treatment: 6.2 months
+ No treatment-related deaths
+ Most common AE was peripheral neuropathy
+
+    – Primarily Grade 1 and 2 sensory
+
+    – Largely reversible
+ Grade 3/4 hematologic toxicity was limited
+ Low rate of infusion reactions observed
+
+   (Grade 1/2)
+ No evidence of cardiac, renal, or hepatic
+
+   toxicity signals
+                                                                                          CBH-1
+
+Brentuximab Vedotin
+Hodgkin Lymphoma Benefit:Risk Profile
+
+Joseph M. Connors, MD, FRCPC
+
+Clinical Director, Centre for Lymphoid Cancer
+British Columbia Cancer Agency
+University of British Columbia
+                                                                                                      CBH-2
+
+Benefit:
+Tumor Reduction
+
+94% (96 of 102)a of patients achieved tumor reduction
+
+a 4 patients not included in analysis (3, no measurable lesions per IRF; 1, no post-baseline scans).
+                                              CBH-3
+
+Benefit:
+Clinically Meaningful Results
+
+                             HL patients ALCL patients
+
+                             N = 102  N = 58
+
+Treatment response           75%      86%
+  Overall response rate      34%      57%
+  Complete remission (CR)    20.5     13.2
+  Median duration of CR, mo
+                              77%      82%
+Symptom resolution           N = 35   N = 17
+ B symptom resolution
+
+NE = Not estimable.
+                                                                                                      CBH-4
+
+Benefit:
+Population in Need: Post-transplant
+
+                100  TTR,  Median                                                               1-yr
+
+                     mo N % OS, yr mortality
+
+                80 > 12 214 28 4.6
+
+Probability, %       0 - 12 542 72 1.2                                                          > 40 %
+
+                60
+
+                40 N = 756
+
+                                                                   p < 0.001
+                20
+
+                     0
+
+                        0 5 10 15 20
+
+                                                       Time from relapse, yr
+
+TTR = Time to relapse.
+Horning et al. 10th International Conference on Malignant Lymphoma; Lugano, Switzerland; 2008.
+                                                                                CBH-5
+
+Treatment of Relapsed or Refractory
+Hodgkin Lymphoma
+
+                                All patients                Post-ASCT patients
+
+                     Evaluable                         Evaluable
+
+Agent                patients, n ORR, n (%) CR, n (%) patients, n ORR, n (%) CR, n (%)
+Vinblastinea
+Vinorelbinea         17         10 (59)       2 (12)   17         10 (59)       2 (12)
+Rituximaba
+Gemcitabinea         22         11 (50)       3 (14)
+Vinorelbine +
+Gemcitabinea         22         5 (23)        1 (5)    18         5 (23)        1 (5)
+Rituximab +
+Gemcitabinea         27         6 (22)        0        16 5 (31) 0
+Bortezomiba
+Bortezomiba          8          6 (75)        4 (50)
+Gem, Vinor, Doxb
+Panobinostatc        33         16 (48)       5 (15)   18         11 (61)
+
+Brentuximab vedotin  14         1 (7)         0        14         1 (7)                                         0
+
+                     30 0 0 28
+
+                     88         62 (70)       17 (19)  36         27 (75)       6 (17)
+
+                     129        35 (27)       5 (4)    129        35 (27)       5 (4)
+
+                     102        77 (75) 35 (34)        102        77 (75) 35 (34)
+
+a Crump M. Hema Am Soc Hematol Educ Prog. 2008:326-333; b Bartlett NL, et al. Ann Oncol. 2007;18(6):1071-1079;
+c Sureda A, et al. 52nd ASH Annual Meeting and Exposition. 2010. Abstract 169.
+                                                                                            CBH-6
+
+Benefit: Risk Ratio
+Relapsed/Refractory Hodgkin Lymphoma
+
+                                     Need
+
+ 50% relapse despite ASCT
+ 72% of relapses occur in less than 1 yr of ASCT
+
+       ~ 40% 1-yr mortality rate
+ All patients become markedly symptomatic
+ Available off-label remedies  short-term benefit in minority of patients
+ High-quality response  opportunity for potentially curative treatment
+
+             Risk                             Benefit
+
+ Peripheral neuropathy                 ORR           75%
+
+– Any grade              55%            CR            34%
+
+– Grade 3                11%            CR duration 20.5 months
+
+ Transient grade 3/4 neutropenia 20%   Potential to make eligible
+                                           for transplant
+ Infusion reactions     12%
+                   SS-1
+
+Supportive Slides
+                                    SS-2
+
+Statistical Methods—Stratification
+
+AETHERA
+
+ Best clinical response achieved after completion of
+   salvage therapy prior to ASCT
+    – CR
+    – PR
+    – SD
+
+ Prior disease status
+    – Refractory
+    – Relapsed < 12 months from the end of frontline therapy
+    – Relapsed ≥ 12 months from the end of frontline therapy
+                                                                                                   SS-3
+
+    Brentuximab Vedotin Studies Ongoing
+    and in Development
+
+Indication Study description                                               Ph 1 Ph 2 Ph 3
+
+              AETHERA—post-ASCT, high-risk HL (placebo controlled)                       X
+
+HL            Combination chemo + brentuximab vedotin in front-line HL     X
+
+              Combination chemo + brentuximab vedotin in front-line HL                   X
+
+ALCL          Combination chemo + brentuximab vedotin in front-line sALCL  X
+              Combination chemo + brentuximab vedotin in front-line sALCL
+                                                                                         X
+
+              Re-treatment                                                    X
+
+CD30+         Cardiac safety (primary data complete)                       X
+malignancies  Drug-drug interaction/Special populations                    X
+              CD30+ NHL
+                                                                                      X
+
+              CD30+ non-lymphomatous malignancies                             X
+
+CTCL          Single agent vs physicians choice in CD30+ CTCL                            X
+
+              Open          In Development
+Complete Remissions by Additional                         SS-4
+Subgroups—March 2011
+                                                       CR / N
+Hodgkin Lymphoma                                       35 / 102
+
+Subgroups                           Overall CRR = 34%   1 /1
+Overall                                                33 / 98
+Age                       12 - 17
+                          18 - 64                       1 /3
+Sex                       ≥ 65                         14 / 48
+                          Male                         21 / 54
+Baseline weight           Female                       29 / 91
+                          ≤ 100 kg
+Relapse                   > 100 kg                      6 / 11
+Refractory                                             21 / 59
+Bone marrow involvement   Present                      14 / 43
+                          Absent
+Baseline LDH              Normal                        0 /8
+                          High                         35 / 94
+Treatments post-ASCT      0                            25 / 65
+                          ≥1                           10 / 37
+Treatments prior to ASCT  ≤2                           17 / 45
+                          >2                           18 / 57
+Prior radiotherapy        Yes                          22 / 57
+                          No                           13 / 45
+                                                       22 / 67
+                                                       13 / 35
+PFSa: Brentuximab Vedotin vs Last                                                            SS-5
+
+Prior Post-ASCT Therapy—March 2011
+
+Hodgkin Lymphoma
+
+                                                                                              Median
+                                                                                             PFS , mo
+
+                  PFS per investigator                                                       7.8
+
+                  PFS most recent prior therapy 4.1
+
+                  HR = 0.41 (p < 0.001)
+
+a PFS as assessed by investigator in the subset of
+patients (n = 57) who received systemic therapy post-ASCT and prior to brentuximab vedotin.
+Combination of Brentuximab Vedotin SS-6
+With ABVD Provides Better Efficacy Than
+Either Agent Alone
+
+Tumor volume, mm3  1200                                                  Untreated
+                                                                         Brentuximab vedotin
+                   1000                                                  (1 mg/kg, q4dx3) ip (4/9 DRs)
+                                                                         ABVD (8/8 CRs / 0/8 DRs)
+                    800                                                  Brentuximab vedotin + ABVD
+                                                                         (9/9/DRs)
+                    600
+                                                                                   L540cy-70B
+                    400
+
+                    200
+
+                        0
+                           0 10 20 30 40 50 60 70 80 90
+
+                                                    Days
+
+ABVD = Doxorubicin (1 mg/kg, q4dx3) iv; bleomycin (7.5 u/kg, q4dx3) ip;
+vinblastine (0.015 mg/kg q4dx3) ip; dacarbazine (20 mg/kg, q3dx4) ip.
+                                                                                                    SS-7
+
+Best Clinical Response by Immunogenicity
+Status in Baseline Negative Patients
+
+Phase 2 Population
+
+                                                                        HL patients, n (%)
+                                                                                n = 96
+
+                                                                        Transient  Persistent
+                                                                                    positive
+                                     Negative positive                                n=7
+
+                                     n = 64                             n = 24
+
+Objective response rate (CR + PR)    49 (77)                            16 (67)             6 (86)
+Disease control rate (CR + PR + SD)
+                                     63 (98)                            22 (92)    7 (100)
+
+                                                                        ALCL patientsa, n (%)
+                                                                                  N = 54
+
+                                                                        Transient  Persistent
+                                                                                    positive
+                                     Negative positive                                n=3
+
+                                     n = 32                             n = 18
+
+Objective response rate (CR + PR)    28 (88)                            15 (83)    3 (100)
+Disease control rate (CR + PR + SD)
+                                     29 (91)                            16 (89)    3 (100)
+
+a Independent review facility assessment per Revised Response Criteria
+for Malignant Lymphoma.
+
\ No newline at end of file
